

## **Timothy Lee, CFA**

timothy.lee@clsa.com +852 2600 8461

Alec So, CFA +852 2600 8742

27 June 2019

## China Materials

Reuters Bloomberg	0868.HK 868 HK
<b>Priced on 26 June</b> HS CEI @ 10,766.	
12M hi/lo HK\$1	10.50/7.59
12M price target ±% potential	HK\$10.90 +32%
Shares in issue Free float (est.)	4,007.3m 43.9%
Market cap	US\$4.2bn
3M ADV	US\$11.3m

Foreign s'holding 52.0%

Major shareholders Lee Yin Yee 22.0% Tung Ching Sai 10.1%

Blended ESG Score (%)*	CLEAN DORCEA
Overall	76.1
Country average	59.0
GEM sector average	65.8
*Click to visit company page on clsa	.com for details

Stock performance (%)



# Xinyi Glass

## HK\$8.24 - BUY

Thanks for your support in the Asiamoney Brokers Poll. Please click here for our voting matrix.



CLSA

# An unsound attack

## Reiterate positive stance on Xinyi Glass despite short-selling report

The accounting research firm recently published a short-selling report on Xinyi Glass, which we found to not consider enough of Xinyi Glass' business operations. Its overseas sales and bank facilities can fund its dividend and overseas Capex, and thus there is no need to remit cash from China. Its better-than-peer profitability is explainable, and an improved float glass industry has resulted in rising onshore cash. We see these arguments as weak in general, and reiterate our positive stance on Xinyi Glass amid recent market capacity reductions, a potential demand pick-up in 2H19, plus capacity expansion to fuel long-term growth momentum; BUY.

#### Short-selling report arguments

(1) The report argues Xinyi Glass has never remitted cash from China to Hong Kong for the payment of dividends, though it has been financed by Hong Kong dollar debt, and thus it is unable to verify its profits; (2) it has shown super-normal profitability relative peers, with a build-up of onshore cash; (3) its Hong Kong business margin appears to have declined and Xinyi Glass did not recognised enough profit in Hong Kong to cover expenses like overhead and interest; (4) the recent disposal of Xinyi Solar Holdings is not necessary given its strong cash on hand; (5) the continuous losses on the disposal of plant and machinery suggest depreciation schedules are not conservative enough; and (6) there was incentive for fraud as there was a lack of cash by end-2014 to refund convertible bonds due in 2017.

#### Our view

(1) It is not wrong to fund dividends using HK\$ debt, given its low borrowing cost (c.2%) vs a withholding tax rate (5%). A steady dividend payout is preferred instead of its cutting dividend in order to save interest/tax costs. Overseas sales (c.30% of overall) also generated FX cash to fund dividends/overseas Capex but not just debt; (2) t has a better margin than Fuyao given less in-house float glass supply on top of a lower-margin US production base for the latter. Rising onshore cash is a result of a recovery of the float glass industry since 2016, plus a shifting expansion focus to overseas; (3) lower profit in Hong Kong due to higher interest/corporate expenses & it may also be due to tax planning; (4) the disposal of its stake in Xinyi Glass was to replenish Hong Kong dollar cash for dividends/overseas Capex; (5) the loss on disposal was immaterial to the prior year's net book amount and depreciation expense; (6) last, its net-gearing ratio of 42% by end-14 was not high and thus it has room to raise debt to refund the convertible bonds instead of manipulation.

### **Reiterate our positive stance**

Our target price is unchanged at HK\$10.90, based on a blend of PE and PB. At a 9.0x 19CL PE with a 6.3% 19CL dividend yield we retain our BUY rating on Xinyi Glass.

Financials					
Year to 31 December	17A	18A	19CL	20CL	21CL
Revenue (HK\$m)	14,728	16,014	17,181	20,167	23,052
Adjusted net profit (HK\$m)	3,697	3,699	3,704	4,851	6,086
Adjusted EPS (HK¢)	91.9	91.7	91.8	120.2	150.8
CL/consensus (11) (EPS%)	-	-	96	93	108
Adj EPS growth (% YoY)	20.1	(0.2)	0.1	31.0	25.5
Adjusted PE (x)	9.0	9.0	9.0	6.9	5.5
Dividend yield (%)	5.8	6.3	6.3	7.2	9.1
FCF yield (%)	(3.5)	1.5	2.9	5.1	7.9
PB (x)	1.8	1.8	1.6	1.4	1.3
ROE (%)	25.6	23.0	21.4	22.0	24.6
Net debt/equity (%)	29.6	28.6	21.0	15.8	8.7
Source: www.clsa.com					

CLSA and CL Securities Taiwan Co., Ltd. ("CLST") do and seek to do business with companies covered in its research reports. As such, investors should be aware that there may be conflicts of interest which could affect the objectivity of the report. Investors should consider this report as only a single factor in making their investment decisions. For important disclosures please refer to page 12.





# Financials at a glance

Depreciation/amortisation         (P21)         (1.004)         (1.003)         (1.009)         (1.009)           Op Ebit         3.399         3.466         3.523         1.6         4.633         5.733           Net interest inc/(exp)         (107)         (142)         (136)         (118)         (97)           Other non-Opitems         1.404         1.644         1.588         (3.4)         1.312         1.444           Profit before tax         4.696         4.970         4.775         0.1         5.826         7.88           Minority interest         0         (11)         (11)         (11)         (11)         (11)           Net profit         4.014         4.237         4.222         (0.4)         4.851         6.060           Cashifowr, (HKSm)         2017A         2016A         2017L         (K YoY)         2020CL         2202CL         2020CL         2020CL<	Year to 31 December	2017A	2018A	2019CL	(% YoY)	2020CL	2021CL
Revenue         14,728         16,014         17,181         7.3         20,167         23,05           Cosy (ac-D6A)         (6,498)         (9,22)         (10,655)         (11,575)         (11,375)         (12,370)           Gross Profit (ac-D6A)         6,290         6,792         7,096         4,5         8,592         9,988         506         (3,048)         (2,866)         (3,048)         (2,866)         (3,048)         (2,866)         (3,048)         (2,866)         (3,048)         (11,030)         (11,030)         (11,030)         (11,01)         (7,01)         (11,01)         (7,01)         (11,01)         (7,01)         (11,01)         (7,02)         (11,01)         (7,02)         (11,01)         (7,02)         (11,01)	Profit & Loss (HK\$m)						
Cogs (ex) GAX         (8,438)         (9,222)         (10,085)         (11,575)         (11,007)           Gross Profit (ex,DAA)         6,290         6,792         7,096         4.5         8,592         9,983           SGAA and other expenses         (1,770)         (2,320)         (2,544)         (2,860)         (1,099)           Depreciation/amoritation         (921)         (1,004)         (1,030)         (1,099)         (1,159)           Op Ebit         3,399         3,466         3,523         1.6         4,633         5,733           Net interest inc.(exp)         (107)         (142)         (1,888)         (1,118)         (07)           Optimon         (1662)         (7,23)         (7,42)         (965)         (1,167)           Profit after tax         4,014         4,233         (0,3)         4,641         6,059           Minority interest         0         (11)		14 728	16 014	17 181	73	20 167	23.052
Grose Profit (ex-DEA)         6.290         6.792         7.096         4.5         8.572         9.988           SGA and other expenses         (1,770)         (2,230)         (2,244)         (2,860)         (3,040)           Op Ebital         3.399         3.468         3.523         1.6         4.433         5.737           Op Ebit         3.399         3.468         3.523         1.6         4.433         5.737           Other non-Op items         1.404         1.644         1.588         (3,4)         1.312         1.444           Profit before tax         4.666         4.970         4.975         0.1         5.526         7.283           Taxation         (682)         (723)         (742)         (110         (111)         (111)         (111)         (111)         (111)         (111)         (111)         (111)         (111)         (113)         (143)         6.080         Castling (HKSm)         2020CL					7.5		
SGAA and other expenses         (1,970)         (2,220)         (2,544)         (2,860)         (1,084)           Depreciation/amoritistion         (211)         (1,004)         (1,030)         (1,079)         (1,158)           Op Ebit         3,399         3,468         3,523         1.6         4,633         5,733           Net interest inc.(exp)         (107)         (142)         (158)         (3,41)         1,111         (111)         (112)         1,444         1,588         (3,41)         1,312         1,444           Profit diter tax         4,646         4,248         4,233         (0,3)         4,661         6,099           Minority interest:         0         (111)         (11)					4.5		
Op Ebitida         4.320         4.472         4.552         1.8         5.732         6.699           Op Ebitid         3.399         3.468         3.523         1.6         4.433         5.737           Net Interest inc/lexp)         1.071         1.142         1.588         (3.4)         1.312         1.444           Pofit before tax         4.696         4.773         0.1         5.526         7.738           Taxation         1.622         7.733         7.423         (4.643         6.091           Minority interest         0         (1.11 <td< td=""><td>· ·</td><td></td><td></td><td>,</td><td>4.5</td><td></td><td></td></td<>	· ·			,	4.5		
Depreciation/amoritation         (921)         (1,004)         (1,007)         (1,097)           Net interest inc/(exp)         (107)         (142)         (136)         (118)         (97)           Net interest inc/(exp)         (107)         (142)         (136)         (118)         (97)           Other non-Opitems         1,404         1,644         1,588         (34)         1,312         1,444           Profit before tax         4,696         4,970         4,775         0.1         5,826         7,884           Minority interest         0         (11)         (11)         (11)         (11)         (11)         (11)           Net profit         4,014         4,237         4,222         (0,4)         4,851         6,060           Cashinow (HKSm)         2017A         2036,         20374         4,01         4,851         6,060           Cashinow (HKSm)         2017A         2036,         20,321         4,643         5,73           Deprecing profit         3,299         3,466         18         4,183         5,140           Other ins-         (1003)         (109)         (1,630)         (2,500)         (2,500)           Deprecing profit         3,254	the second se				1.8		6,898
Op Ebit         3,399         3,468         3,223         1.4         4,633         5,73           Net interest inc.(exp)         (107)         (142)         (136)         (118)         (97)           Other non-Op items         1,404         1,644         1,588         (3.4)         1,312         1,444           Porfit before tax         4,696         4,970         4,975         0.1         5.826         7.288           Taxation         (682)         (723)         (742)         (4851         6.099           Minority interest         0         (11)	•						(1,158)
Net interest inc/(exp)         (107)         (142)         (136)         (118)         (97)           Other non-Opi tems         1.404         1.644         1.588         (3.4)         1.312         1.444           Profit before tax         4.696         4.970         4.975         0.1         5.826         7.88           Profit after tax         4.014         4.248         4.233         (0.3)         4.861         6.09           Minority interest         0         (11)         (11)         (11)         (11)         (11)           Net profit         3.697         3.699         3.704         0.1         4.851         6.09           Cashitow (HK\$m)         2017A         2018A         2.015CL         (¥ YY)         2020CL         2022C           Operating profit         3.399         3.468         3.523         1.6         4.633         5.73           Working capital changes         (1.32)         (441)         (119)         (365)         (355)           Other tems         (01)         (1.053)         (967)         (1.163)         (1.400)           Profit changes         (1.32)         (441)         (1.09)         (1.60)         (2.500)         (2.500)         (2.500) <td>•</td> <td>3,399</td> <td></td> <td></td> <td>1.6</td> <td></td> <td>5,739</td>	•	3,399			1.6		5,739
Profit before tax         4.696         4.970         4.975         0.1         5.826         7.283           Profit after tax         4.014         4.248         4.233         (0.3)         4.861         6.090           Minority interest         0         (1.11)         (1.1			(142)				(97)
Taxation         (682)         (723)         (742)         (965)         (1,18)           Minority interest         0         (11)	Other non-Op items	1,404	1,644	1,588	(3.4)	1,312	1,641
Profit atter tax         4,014         4,248         4,233         (0.3)         4,861         6,609           Minority interest         0         (11)	Profit before tax	4,696	4,970	4,975	0.1	5,826	7,283
Minority interest         0         (11)	Taxation	(682)	(723)	(742)		(965)	(1,187)
Net profit         4.014         4.227         0.4         4.851         6.080           Adjusted profit         3.697         3.699         3.704         0.1         4.851         6.080           Cashfiow (HK\$m)         2017A         2018A         2019CL         (% YoY)         2020CL         2021CL           Operating profit         3.399         3.468         3.523         1.6         4.633         5.737           Depreciation/mortisation         921         1.004         1.003         2.6         1.099         1.153           Other items         (901)         (1.53)         (667)         (1.181)         (1.483)         (5.14)           Net operating cashflow         (1.186)         485         966         99.1         1.683         2.640           KéA/Otters         1.448         1.705         2.081         2.2.1         1.401         1.74           Net investing cashflow         (1.180)         (748)         (419)         (1.099)         (753           Increase in leans         792         1.503         (634)         1.62         (561)           Dividends         1.926         (2.078)         (2.077)         (2.836)         (2.836)         (2.836)         (2.836)<		,			(0.3)		6,096
Adjusted profit         3,697         3,704         0.1         4,851         6,08.           Cashflow (HKSm)         2017A         2018A         2019CL         (% YoY)         2020CL         2021C           Operating profit         3,399         3,468         3,523         1.6         4,633         5,737           Depreciation/amortisation         9,21         1,004         1,030         2.6         1,099         1,155           Working capital changes         (1,32)         (481)         (119)         (365)         (358)           Other items         (901)         (1,053)         (967)         (1,183)         (1,440)           Capital expenditure         (3,254)         (2,453)         (2,500)         (2,500)         (2,500)           Free cashflow         (1,168)         485         966         99.1         1,683         2,644           NeX/Otters         1,448         1,705         2,061         2,21         1,401         1,744           Net financing cashflow         1,264         (2,078)         (2,077)         (2,386)         (2,590)           Increase in loans         772         1,535         (5,652)         (5,555         (5,753)         660         833							(11)
Cashflow (HKSm)         2017A         2018A         2019CL         (% YoY)         2020CL         2021CL           Operating profit         3,399         3,468         3,523         1.6         4,633         5,733           Depreciation/amortisation         921         1,004         1,013         2.6         1,099         1,151           Working capital changes         (1,323)         (441)         (119)         (365)         (356)           Other items         (901)         (1,053)         (967)         (1,181)         (1,403)           Net operating cashflow         2,086         2,938         3,466         18         4,183         5,144           Capital expenditure         (3,254)         (2,453)         (2,500)         (2,500)         (2,500)         (2,500)         (2,500)         (2,500)         (2,500)         (2,501)         (1,029)         (7,54)         (2,620)         (2,077)         (2,386)         (2,944)         (516)         (1,926)         (2,077)         (2,386)         (2,594)         (2,220)         (3,555)         Incr/(decr) in net cash         283         1,562         336         (78.5)         Babac         833         1,562         336         (78.5)         Babac         R33         1,512 <td></td> <td>,</td> <td></td> <td></td> <td></td> <td></td> <td>6,086</td>		,					6,086
Operating profit         3.399         3.468         3.523         1.6         4.433         5.733           Depreciation/amortisation         921         1.004         1.030         2.6         1.099         1.135           Orking capital changes         (1.332)         (461)         (119)         (365)         (358)           Other items         (901)         (1.053)         (967)         (1.183)         (1.433)           Net operating cashflow         (3.254)         (2.453)         (2.500)         (2.500)         (2.500)           Free cashflow         (1.168)         445         966         99.1         1.683         2.644           M&A/Others         1.448         1.705         2.081         2.21         1.401         1.74           Net investing cashflow         (1.806)         (748)         (419)         (1.099)         (754)           Increase in loans         792         1.503         (634)         162         (564)           Dividends         (1.926)         (2.078)         (2.077)         (2.386)         (840)           Increase in loans         7.92         1.503         (551)         (560)         833         (563)         (574)         2020CL         2.2215)	Adjusted profit	3,697	3,699	3,704	0.1	4,851	6,086
Depreciation/amortisation         921         1.004         1.030         2.6         1.099         1.153           Working capital changes         (1.332)         (481)         (119)         (365)         (358)           Other items         (901)         (1.053)         (967)         (1.183)         (1.400)           Net operating cashflow         2.086         2.938         3.466         18         4.183         5,144           Capital expenditure         (3.254)         (2.450)         (2.500)         (2.500)         (2.500)           Free cashflow         (1.168)         485         966         99.1         1.683         2.64           Net investing cashflow         (1.806)         (748)         (419)         (1.099)         (754)           Increace in loans         792         1.503         (634)         162         (564)           Dividends         (1.926)         (2.078)         (2077)         (2.386)         (2.994)           Net tinancing cashflow         2         628         (2.711)         (2.225)         (3.555           Incr/(dec) in net cash         2.83         1.562         3.36         3.268         3.401         4.1         3.679         3.629           <	Cashflow (HK\$m)	2017A	2018A	2019CL	(% YoY)		2021CL
Working capital changes         (1,32)         (441)         (119)         (365)         (358)           Other items         (901)         (1,053)         (967)         (1,183)         (1,400)           Net operating cashflow         2,086         2,938         3,466         18         4,183         5,144           Capital expenditure         (3,254)         (2,453)         (2,500)         (2,500)         (2,500)           Free cashflow         (1,168)         485         966         99.1         1,683         2,644           McKinothers         1,448         1,705         2,031         2.2.1         1,401         1,744           Net investing cashflow         (1,206)         (2,078)         (2,077)         (2,366)         (2,94)           Net equity raised/other         1,136         (53)         -         -         -         -           Net quity raised/other         1,136         (53)         -			,			,	5,739
Other items         (901)         (1,053)         (967)         (1,183)         (1,403)           Net operating cashflow         2,086         2,938         3,466         1.8         4,183         5,144           Capital expenditure         (3,254)         (2,453)         (2,500)         (2,500)         (2,500)         (2,500)           Free cashflow         (1,168)         485         966         99.1         1,683         2,644           Net investing cashflow         (1,090)         (754         (1,109)         (754           Increase in loans         792         1,503         (634)         1.62         (551           Dividends         (1,926)         (2,077)         (2,386)         (2,925)         (3,555           Incr/(der) in net cash         283         1,562         336         (78.5)         860         83           Sch rate movements         - <td></td> <td></td> <td>,</td> <td></td> <td>2.6</td> <td></td> <td>1,158</td>			,		2.6		1,158
Net operating cashflow       2,086       2,938       3,466       18       4,183       5,144         Capital expenditure       (3,254)       (2,453)       (2,500)       (2,500)       (2,500)       (2,500)       (2,500)       (2,500)       (2,500)       (2,500)       (2,500)       (2,500)       (2,500)       (2,500)       (2,500)       (2,500)       (2,500)       (2,500)       (2,500)       (2,500)       (1,683)       2,644         McKiny Chthers       1,448       1,705       2,081       22.1       1,401       1,744         Net requity raised/other       1,136       (53)       (2,078)       (2,278)       (2,294)       (2,294)         Net equity raised/other       1,136       (53)       - <t< td=""><td></td><td></td><td></td><td></td><td></td><td>. ,</td><td></td></t<>						. ,	
Capital expenditure       (3,254)       (2,453)       (2,500)       (2,500)         Free cashflow       (1,168)       485       966       99.1       1,683       2,644         McA/Others       1,448       1,705       2,081       22.1       1,401       1,744         Net investing cashflow       (1,926)       (2,078)       (2,071)       (2,386)       (2,994         Net equity raised/other       1,136       (53)       -       -       -       -         Net financing cashflow       2       (628)       (2,711)       (2,225)       (3,555         Incr/(dcr) in net cash       283       1,562       336       (78.5)       860       833         Exch rate movements       -							
Free cashflow         (1,168)         485         966         99.1         1,683         2,444           M&A/Others         1,448         1,705         2.081         22.1         1,401         1,744           Net investing cashflow         (1,806)         (748)         (419)         (1,099)         (754)           Increase in loans         792         1,503         (634)         1.62         (553)           Net equity raised/other         1,136         (53)         -         -         -           Net financing cashflow         2         (628)         (2,711)         (2,225)         (3,555)           State expect (HKSm)         2015A         2019CL         (% YoY)         2020CL         2020CL <td< td=""><td></td><td></td><td></td><td>· ·</td><td>18</td><td></td><td></td></td<>				· ·	18		
M&A/Others       1,448       1.705       2.081       22.1       1,401       1,744         Net investing cashflow       (1,806)       (748)       (419)       (1,099)       (754         Increase in loans       792       1,503       (634)       162       (516)         Dividends       (1,926)       (2,078)       (2,071)       (2,286)       (2,994)         Net equity raised/other       1,136       (53)       -       -       -         Net financing cashflow       2       (628)       (2,711)       (2,225)       (3,555)         Incr/(der) in net cash       283       1,562       336       (78.5)       860       833         Exch rate movements       -					00.4		
Net investing cashflow         (1,806)         (748)         (14)         (1,099)         (754           Increase in loans         792         1,503         (634)         162         (561)           Increase in loans         (1,926)         (2,078)         (2,077)         (2,386)         (2,994)           Net equity raised/other         1,136         (53)         -							
Increase in loans       792       1.503       (6.4)       162       (541         Dividends       (1,926)       (2.078)       (2.077)       (2.386)       (2.978)         Net equity raised/other       1.136       (53)       -       -         Net financing cashflow       2       (628)       (2.711)       (2.225)       (3.555         Incr(decr) in et cash       283       1.562       336       (78.5)       860       833         Exch rate movements       -					22.1		
Dividends         (1,926)         (2,078)         (2,077)         (2,386)         (2,994           Net equity raised/other         1,136         (53)         -         -         -           Net financing cashflow         2         (628)         (2,711)         (2,225)         (3,555           Incr/(decr) in net cash         283         1,562         336         (78.5)         860         833           Exch rate movements         -							
Net equity raised/other       1,136       (53)       -       -         Net financing cashflow       2       (628)       (2,711)       (2,225)       (3,555)         Incr/(decr) in net cash       283       1,562       336       (78.5)       8600       833         Exch rate movements       -       -       -       -       -       -       -       -         Balance sheet (HKSm)       2017A       2018A       2019CL       (% YoY)       2020CL       2020CL       2020CL       2020CL         Cash & equivalents       3,051       4,613       4,949       7.3       5.809       6,664         Accounts receivable       1,243       1,352       5.8       1,587       1,814         Other current assets       1,632       1,909       14,635       11.9       16,119       17,543         Investments       4,416       4,724       4,309       (8.8)       4,309       4,309         Intersts       3,477       3,812       3,727       (2.2)       3,644       3,562         Other non-current assets       1,532       1,906       1,906       1,906       1,906       1,906       1,906         Other current labs       2,166       2							
Net financing cashflow         2         (628)         (2,711)         (2,255)         (3,555)           Incr/(decr) in net cash         283         1,562         336         (78.5)         860         837           Exch rate movements         - <td></td> <td></td> <td></td> <td>(2,077)</td> <td></td> <td>(2,300)</td> <td>(2,774)</td>				(2,077)		(2,300)	(2,774)
Incr/(decr) in net cash       283       1,562       336       (78.5)       860       833         Exch rate movements       -		,		(2 711)		(2 225)	(3 555)
Exch rate movements         -					(78.5)		831
Cash & equivalents $3,051$ $4,613$ $4,949$ $7.3$ $5,809$ $6,644$ Accounts receivable $1,243$ $1,278$ $1,352$ $5.8$ $1,587$ $1,817$ Other current assets $3,638$ $3,268$ $3,401$ $4.1$ $3,679$ $3,955$ Fixed assets $12,929$ $13,079$ $14,635$ $11.9$ $16,119$ $17,544$ Investments $4,416$ $4,724$ $4,309$ $(8.8)$ $4,309$ $4,309$ Intangible assets $3,497$ $3,812$ $3,727$ $(2.2)$ $3,644$ $3,566$ Other non-current assets $1,532$ $1,906$ $1,906$ $0$ $1,906$ Total assets $30,305$ $32,679$ $34,278$ $4.9$ $37,052$ $39,733$ Short-term debt $2,068$ $3,094$ $2,898$ $(6.4)$ $2,948$ $2,777$ Accounts payable $923$ $920$ $1,007$ $9,5$ $1,156$ $1,300$ Other current liabs $2,166$ $2,588$ $2,588$ $0$ $2,588$ $2,588$ $0$ $2,588$ $2,588$ $0$ $2,588$ $2,588$ $0$ $2,588$ $2,588$ $0$ $2,588$ $2,588$ $0$ $2,588$ $2,588$ $0$ $2,588$ $2,588$ $0$ $2,588$ $2,588$ $0$ $2,588$ $2,588$ $0$ $2,588$ $2,588$ $0$ $2,588$ $2,588$ $0$ $2,588$ $2,588$ $0$ $2,588$ $2,588$ $0$ $2,588$ $2,588$ $0$ $2,588$ $2,588$ $0$ $2$		-	-	-	(, 0.0)	-	-
Cash & equivalents $3,051$ $4,613$ $4,949$ $7.3$ $5,809$ $6,644$ Accounts receivable $1,243$ $1,278$ $1,352$ $5.8$ $1,587$ $1,817$ Other current assets $3,638$ $3,268$ $3,401$ $4.1$ $3,679$ $3,955$ Fixed assets $12,929$ $13,079$ $14,635$ $11.9$ $16,119$ $17,544$ Investments $4,416$ $4,724$ $4,309$ $(8.8)$ $4,309$ $4,300$ Intangible assets $3,497$ $3,812$ $3,727$ $(2.2)$ $3,644$ $3,566$ Other non-current assets $1,532$ $1,906$ $1,906$ $0$ $1,906$ Total assets $30,305$ $32,679$ $34,278$ $4.9$ $37,052$ $39,733$ Short-term debt $2,068$ $3,094$ $2,898$ $(6.4)$ $2,948$ $2,773$ Accounts payable $923$ $920$ $1,007$ $9,5$ $1,156$ $1,300$ Other current liabs $2,166$ $2,588$ $2,588$ $0$ $2,588$ $2,588$ Long-term debt/CBs $6,399$ $6,875$ $6,437$ $(6.4)$ $6,549$ $6,632$ Provisions/other LT liabs $443$ $499$ $499$ $0$ $499$ $492$ Minorities/other equity $69$ $78$ $78$ $0$ $78$ $77$ Total liabs & equity $30,305$ $32,679$ $34,278$ $4.9$ $37,052$ $39,733$ Ratio analysis $2017A$ $2018A$ $2019CL$ $(X YoY)$ $2020CL$ $2$	Balance sheet (HK\$m)	2017A	2018A	2019CL	(% YoY)	2020CL	2021CL
Other current assets         3,638         3,268         3,401         4.1         3,679         3,955           Fixed assets         12,929         13,079         14,635         11.9         16,119         17,544           Investments         4,416         4,724         4,309         (8.8)         4,309         4,309           Intangible assets         3,497         3,812         3,727         (2.2)         3,644         3,565           Other non-current assets         1,532         1,906         1,906         0         1,906         1,906           Total assets         30,305         32,679         34,278         4.9         37,052         39,733           Short-term debt         2,068         3,094         2,898         (6,4)         2,948         2,777           Accounts payable         923         920         1,007         9.5         1,156         1,300           Other current liabs         2,166         2,588         2,588         0         2,588         2,588           Long-term debt/CBs         6,399         6,875         6,437         (6,4)         6,439         4,99         99         9         9         77         704         14.5         32,234		3,051	4,613	4,949		5,809	6,640
Fixed assets       12,929       13,079       14,635       11.9       16,119       17,542         Investments       4,416       4,724       4,309       (8.8)       4,309       4,309         Intangible assets       3,497       3,812       3,727       (2.2)       3,644       3,560         Other non-current assets       1,532       1,906       1,906       0       1,906       1,906         Total assets       30,305       32,679       34,278       4.9       37,052       39,733         Short-term debt       2,068       3,094       2,898       (6.4)       2,948       2,773         Accounts payable       923       920       1,007       9.5       1,156       13,300         Other current liabs       2,166       2,588       2,588       0       2,588       16,437         Chory-term debt/CBs       6,399       6,875       6,437       (6.4)       6,549       6,166         Provisions/other LT liabs       18,237       18,625       20,770       11.5       23,234       26,320         Shareholder funds       18,237       18,2679       34,278       4.9       37,052       39,733         Ratio analysis       2017A       201	Accounts receivable	1,243	1,278	1,352	5.8	1,587	1,814
Investments         4,416         4,724         4,309         (8.8)         4,309         4,309           Intangible assets         3,497         3,812         3,727         (2.2)         3,644         3,562           Other non-current assets         1,532         1,906         1,906         0         1,906         1,906           Total assets         30,305         32,679         34,278         4.9         37,052         39,733           Short-term debt         2,068         3,094         2,898         (6.4)         2,948         2,773           Accounts payable         923         920         1,007         9.5         1,156         1,300           Other current liabs         2,166         2,588         2,588         0         2,588         2,588           Long-term debt/CBs         6,399         6,875         6,437         (6.4)         6,549         6,132           Provisions/other LT liabs         443         499         499         0         499         499           Shareholder funds         18,237         18,625         20,770         11.5         23,234         26,320           Ratio analysis         2017A         2018A         2019CL         (% YoY)	Other current assets	3,638	3,268	3.401	4.1	3,679	3.959
Intangible assets         3,497         3,812         3,727         (2.2)         3,644         3,562           Other non-current assets         1,532         1,906         1,906         0         1,906         1,906           Total assets         30,305         32,679         34,278         4.9         37,052         39,733           Short-term debt         2,068         3,094         2,898         (6.4)         2,948         2,773           Accounts payable         923         920         1,007         9.5         1,156         1,300           Other current liabs         2,166         2,588         2,588         0         2,588         2,588           Long-term debt/CBs         6,379         6,875         6,437         (6.4)         6,549         6,165           Provisions/other LT liabs         443         499         499         0         499         499         37,052         39,733           Shareholder funds         18,237         18,625         20,770         11.5         23,234         26,320           Minorities/other equity         69         78         78         0         78         74           Total liabs & equity         30,305         32,679	Fixed assets	40.000					-,
Other non-current assets         1,532         1,906         1,906         0         1,906         1,906           Total assets         30,305         32,679         34,278         4.9         37,052         39,733           Short-term debt         2,068         3,094         2,898         (6.4)         2,948         2,773           Accounts payable         923         920         1,007         9.5         1,156         1,306           Other current liabs         2,166         2,588         2,588         0         2,588         2,588           Long-term debt/CBs         6,399         6,875         6,437         (6.4)         6,549         6,166           Provisions/other LT liabs         443         499         499         0         499         499         0         499         493         505         50,532         493         50,532		12,929	13,079		11.9		17,542
Total assets30,30532,67934,2784.937,05239,733Short-term debt2,0683,0942,898(6.4)2,9482,773Accounts payable9239201,0079.51,1561,300Other current liabs2,1662,5882,58802,5882,588Long-term debt/CBs6,3996,8756,437(6.4)6,5496,166Provisions/other LT liabs4434994990499499Shareholder funds18,23718,62520,77011.523,23426,324Minorities/other equity69787807877Total liabs & equity30,30532,67934,2784.937,05239,733Ratio analysis2017A2018A2019CL(% YoY)2020CL2021CLEbitd margin (%)29,327,926.528.429.929.9Ebit margin (%)24.95.6(0.4)14.925.9Op cashflow growth (% YoY)(15.0)40.818.020.722.9Capex/sales (%)22.115.314.612.410.0Net debt/Ebitda (x)1.31.21.00.60.1ROE (%)25.623.021.422.024.4	Investments	,		14,635		16,119	
Short-term debt       2,068       3,094       2,898       (6.4)       2,948       2,773         Accounts payable       923       920       1,007       9.5       1,156       1,300         Other current liabs       2,166       2,588       2,588       0       2,588       2,588         Long-term debt/CBs       6,399       6,875       6,437       (6.4)       6,549       6,167         Provisions/other LT liabs       443       499       499       0       499       499         Shareholder funds       18,237       18,625       20,770       11.5       23,234       26,327         Minorities/other equity       69       78       78       0       78       73         Total liabs & equity       30,305       32,679       34,278       4.9       37,052       39,732         Revenue growth (% YoY)       14.6       8.7       7.3       17.4       14.3         Ebitda margin (%)       29.3       27.9       26.5       28.4       29.9         Ebit margin (%)       23.1       21.7       20.5       23.0       24.9         Op cashflow growth (% YoY)       (15.0)       40.8       18.0       20.7       22.0 <td< td=""><td></td><td>4,416 3,497</td><td>4,724 3,812</td><td>14,635 4,309 3,727</td><td>(8.8)</td><td>16,119 4,309 3,644</td><td>17,542 4,309 3,562</td></td<>		4,416 3,497	4,724 3,812	14,635 4,309 3,727	(8.8)	16,119 4,309 3,644	17,542 4,309 3,562
Accounts payable9239201,0079.51,1561,300Other current liabs2,1662,5882,58802,5882,588Long-term debt/CBs6,3996,8756,437(6.4)6,5496,162Provisions/other LT liabs4434994990499499Shareholder funds18,23718,62520,77011.523,23426,320Minorities/other equity69787807877Total liabs & equity30,30532,67934,2784.937,05239,737Ratio analysis2017A2018A2019CL(% YoY)2020CL2021CLRevenue growth (% YoY)14.68.77.317.414.4Ebitd amargin (%)29.327.926.528.429.9Ebit margin (%)24.95.6(0.4)14.925.5Op cashflow growth (% YoY)(15.0)40.818.020.722.4Net debt/equity (%)29.628.621.015.88.5Net debt/Ebitda (x)1.31.21.00.60.3ROE (%)25.623.021.422.024.4	Intangible assets	4,416 3,497 1,532	4,724 3,812 1,906	14,635 4,309 3,727 1,906	(8.8) (2.2) 0	16,119 4,309 3,644 1,906	17,542 4,309 3,562 1,906
Other current liabs2,1662,5882,58802,5882,588Long-term debt/CBs6,3996,8756,437(6.4)6,5496,162Provisions/other LT liabs4434994990499499Shareholder funds18,23718,62520,77011.523,23426,320Minorities/other equity69787807878Total liabs & equity30,30532,67934,2784.937,05239,733Ratio analysis2017A2018A2019CL(% YoY)2020CL2021CLRevenue growth (% YoY)14.68.77.317.414.4Ebitda margin (%)29.327.926.528.429.9Ebit margin (%)23.121.720.523.024.4Op cashflow growth (% YoY)(15.0)40.818.020.722.2Op cashflow growth (% YoY)15.888.10.31.21.00.60.3Net debt/equity (%)29.628.621.015.88.8.8.Net debt/Ebitda (x)1.31.21.00.60.30.60.3Roce (%)25.623.021.422.024.422.024.4	Intangible assets Other non-current assets <b>Total assets</b>	4,416 3,497 1,532 <b>30,305</b>	4,724 3,812 1,906 <b>32,679</b>	14,635 4,309 3,727 1,906 <b>34,278</b>	(8.8) (2.2) 0 <b>4.9</b>	16,119 4,309 3,644 1,906 <b>37,052</b>	17,542 4,309 3,562 1,906 <b>39,732</b>
Long-term debt/CBs $6,399$ $6,875$ $6,437$ $(6.4)$ $6,549$ $6,162$ Provisions/other LT liabs $443$ $499$ $499$ $0$ $499$ $499$ $499$ Shareholder funds $18,237$ $18,625$ $20,770$ $11.5$ $23,234$ $26,320$ Minorities/other equity $69$ $78$ $78$ $0$ $78$ $78$ Total liabs & equity $30,305$ $32,679$ $34,278$ $4.9$ $37,052$ $39,732$ Ratio analysis $2017A$ $2018A$ $2019CL$ $(\% YoY)$ $2020CL$ $2021CL$ Revenue growth (% YoY) $14.6$ $8.7$ $7.3$ $17.4$ $14.2$ Ebitda margin (%) $29.3$ $27.9$ $26.5$ $28.4$ $29.42$ Ebit margin (%) $23.1$ $21.7$ $20.5$ $23.0$ $24.4$ Op cashflow growth (% YoY) $(15.0)$ $40.8$ $18.0$ $20.7$ $22.7$ Capex/sales (%) $22.1$ $15.3$ $14.6$ $12.4$ $10.6$ Net debt/equity (%) $29.6$ $28.6$ $21.0$ $15.8$ $8.7$ Net debt/Ebitda (x) $1.3$ $1.2$ $1.0$ $0.6$ $0.7$ ROE (%) $25.6$ $23.0$ $21.4$ $22.0$ $24.4$	Intangible assets Other non-current assets <b>Total assets</b> Short-term debt	4,416 3,497 1,532 <b>30,305</b> 2,068	4,724 3,812 1,906 <b>32,679</b> 3,094	14,635 4,309 3,727 1,906 <b>34,278</b> 2,898	(8.8) (2.2) 0 <b>4.9</b> (6.4)	16,119 4,309 3,644 1,906 <b>37,052</b> 2,948	17,542 4,309 3,562 1,906 <b>39,732</b> 2,773
Provisions/other LT liabs4434994990499499Shareholder funds18,23718,62520,77011.523,23426,320Minorities/other equity69787807878Total liabs & equity30,30532,67934,2784.937,05239,732Ratio analysis2017A2018A2019CL(% YoY)2020CL2021CLRevenue growth (% YoY)14.68.77.317.414.3Ebitda margin (%)29.327.926.528.429.9Ebit margin (%)23.121.720.523.024.4Net profit growth (% YoY)(15.0)40.818.020.722.5Capex/sales (%)22.115.314.612.410.4Net debt/equity (%)29.628.621.015.88.5Net debt/Ebitda (x)1.31.21.00.60.3ROE (%)25.623.021.422.024.4	Intangible assets Other non-current assets <b>Total assets</b> Short-term debt Accounts payable	4,416 3,497 1,532 <b>30,305</b> 2,068 923	4,724 3,812 1,906 <b>32,679</b> 3,094 920	14,635 4,309 3,727 1,906 <b>34,278</b> 2,898 1,007	(8.8) (2.2) 0 <b>4.9</b> (6.4) 9.5	16,119 4,309 3,644 1,906 <b>37,052</b> 2,948 1,156	17,542 4,309 3,562 1,906 <b>39,732</b> 2,773 1,306
Shareholder funds18,23718,62520,77011.523,23426,320Minorities/other equity69787807878Total liabs & equity30,30532,67934,2784.937,05239,733Ratio analysis2017A2018A2019CL(% YoY)2020CL2021CLRevenue growth (% YoY)14.68.77.317.414.3Ebitda margin (%)29.327.926.528.429.9Ebit margin (%)23.121.720.523.024.9Op cashflow growth (% YoY)(15.0)40.818.020.722.9Capex/sales (%)22.115.314.612.410.4Net debt/equity (%)29.628.621.015.88.1Net debt/Ebitda (x)1.31.21.00.60.3ROE (%)25.623.021.422.024.4	Intangible assets Other non-current assets <b>Total assets</b> Short-term debt Accounts payable Other current liabs	4,416 3,497 1,532 <b>30,305</b> 2,068 923 2,166	4,724 3,812 1,906 <b>32,679</b> 3,094 920 2,588	14,635 4,309 3,727 1,906 <b>34,278</b> 2,898 1,007 2,588	(8.8) (2.2) 0 <b>4.9</b> (6.4) 9.5 0	16,119 4,309 3,644 1,906 <b>37,052</b> 2,948 1,156 2,588	17,542 4,309 3,562 1,906 <b>39,732</b> 2,773 1,306 2,588
Minorities/other equity69787807878Total liabs & equity30,30532,67934,2784.937,05239,733Ratio analysis2017A2018A2019CL(% YoY)2020CL2021CLRevenue growth (% YoY)14.68.77.317.414.5Ebitda margin (%)29.327.926.528.429.5Ebit margin (%)23.121.720.523.024.5Net profit growth (% YoY)(15.0)40.818.020.722.5Op cashflow growth (% YoY)(15.0)40.818.020.722.5Net debt/equity (%)29.628.621.015.88.1Net debt/Ebitda (x)1.31.21.00.60.1ROE (%)25.623.021.422.024.0	Intangible assets Other non-current assets <b>Total assets</b> Short-term debt Accounts payable Other current liabs Long-term debt/CBs	4,416 3,497 1,532 <b>30,305</b> 2,068 923 2,166 6,399	4,724 3,812 1,906 <b>32,679</b> 3,094 920 2,588 6,875	14,635 4,309 3,727 1,906 <b>34,278</b> 2,898 1,007 2,588 6,437	(8.8) (2.2) 0 4.9 (6.4) 9.5 0 (6.4)	16,119 4,309 3,644 1,906 <b>37,052</b> 2,948 1,156 2,588 6,549	17,542 4,309 3,562 1,906 <b>39,732</b> 2,773 1,306 2,588 6,162
Total liabs & equity30,30532,67934,2784.937,05239,733Ratio analysis2017A2018A2019CL(% YoY)2020CL2021CLRevenue growth (% YoY)14.68.77.317.414.3Ebitda margin (%)29.327.926.528.429.9Ebit margin (%)23.121.720.523.024.9Net profit growth (%)24.95.6(0.4)14.925.4Op cashflow growth (% YoY)(15.0)40.818.020.722.9Capex/sales (%)22.115.314.612.410.4Net debt/equity (%)29.628.621.015.88.1Net debt/Ebitda (x)1.31.21.00.60.1ROE (%)25.623.021.422.024.4	Intangible assets Other non-current assets <b>Total assets</b> Short-term debt Accounts payable Other current liabs Long-term debt/CBs Provisions/other LT liabs	4,416 3,497 1,532 <b>30,305</b> 2,068 923 2,166 6,399 443	4,724 3,812 1,906 <b>32,679</b> 3,094 920 2,588 6,875 499	14,635 4,309 3,727 1,906 <b>34,278</b> 2,898 1,007 2,588 6,437 499	(8.8) (2.2) 0 (6.4) 9.5 0 (6.4) 0	16,119 4,309 3,644 1,906 <b>37,052</b> 2,948 1,156 2,588 6,549 499	17,542 4,309 3,562 1,906 <b>39,732</b> 2,773 1,306 2,588 6,162 499
Ratio analysis2017A2018A2019CL(% YoY)2020CL2021CLRevenue growth (% YoY)14.68.77.317.414.3Ebitda margin (%)29.327.926.528.429.9Ebit margin (%)23.121.720.523.024.9Net profit growth (%)24.95.6(0.4)14.925.5Op cashflow growth (% YoY)(15.0)40.818.020.722.9Capex/sales (%)22.115.314.612.410.4Net debt/equity (%)29.628.621.015.88.7Net debt/Ebitda (x)1.31.21.00.60.3ROE (%)25.623.021.422.024.4	Intangible assets Other non-current assets <b>Total assets</b> Short-term debt Accounts payable Other current liabs Long-term debt/CBs Provisions/other LT liabs Shareholder funds	4,416 3,497 1,532 <b>30,305</b> 2,068 923 2,166 6,399 443 18,237	4,724 3,812 1,906 <b>32,679</b> 3,094 920 2,588 6,875 499 18,625	14,635 4,309 3,727 1,906 <b>34,278</b> 2,898 1,007 2,588 6,437 499 20,770	(8.8) (2.2) 0 4.9 (6.4) 9.5 0 (6.4) 0 (6.4) 0 11.5	16,119 4,309 3,644 1,906 <b>37,052</b> 2,948 1,156 2,588 6,549 499 23,234	17,542 4,309 3,562 1,906 <b>39,732</b> 2,773 1,306 2,588 6,162 499 26,326
Revenue growth (% YoY)14.68.77.317.414.3Ebitda margin (%)29.327.926.528.429.3Ebit margin (%)23.121.720.523.024.4Net profit growth (%)24.95.6(0.4)14.925.3Op cashflow growth (% YoY)(15.0)40.818.020.722.2Capex/sales (%)22.115.314.612.410.4Net debt/equity (%)29.628.621.015.88.3Net debt/Ebitda (x)1.31.21.00.60.3ROE (%)25.623.021.422.024.4	Intangible assets Other non-current assets <b>Total assets</b> Short-term debt Accounts payable Other current liabs Long-term debt/CBs Provisions/other LT liabs Shareholder funds Minorities/other equity	4,416 3,497 1,532 <b>30,305</b> 2,068 923 2,166 6,399 443 18,237 69	4,724 3,812 1,906 <b>32,679</b> 3,094 920 2,588 6,875 499 18,625 78	14,635 4,309 3,727 1,906 <b>34,278</b> 2,898 1,007 2,588 6,437 499 20,770 78	(8.8) (2.2) 0 (6.4) 9.5 0 (6.4) 0 11.5 0	16,119 4,309 3,644 1,906 <b>37,052</b> 2,948 1,156 2,588 6,549 499 23,234 78	17,542 4,309 3,562 1,906 <b>39,732</b> 2,773 1,306 2,588 6,162 499 26,326 78
Ebitda margin (%)29.327.926.528.429.9Ebit margin (%)23.121.720.523.024.9Net profit growth (%)24.95.6(0.4)14.925.3Op cashflow growth (% YoY)(15.0)40.818.020.722.0Capex/sales (%)22.115.314.612.410.4Net debt/equity (%)29.628.621.015.88.3Net debt/Ebitda (x)1.31.21.00.60.3ROE (%)25.623.021.422.024.4	Intangible assets Other non-current assets <b>Total assets</b> Short-term debt Accounts payable Other current liabs Long-term debt/CBs Provisions/other LT liabs Shareholder funds Minorities/other equity <b>Total liabs &amp; equity</b>	4,416 3,497 1,532 <b>30,305</b> 2,068 923 2,166 6,399 443 18,237 69 <b>30,305</b>	4,724 3,812 1,906 <b>32,679</b> 3,094 920 2,588 6,875 499 18,625 78 <b>32,679</b>	14,635 4,309 3,727 1,906 <b>34,278</b> 2,898 1,007 2,588 6,437 499 20,770 78 <b>34,278</b>	(8.8) (2.2) 0 4.9 (6.4) 9.5 0 (6.4) 0 11.5 0 4.9	16,119 4,309 3,644 1,906 <b>37,052</b> 2,948 1,156 2,588 6,549 499 23,234 78 <b>37,052</b>	17,542 4,309 3,562 1,906 <b>39,732</b> 2,773 1,306 2,588 6,162 499 26,326 78 <b>39,732</b>
Ebit margin (%)23.121.720.523.024.9Net profit growth (%)24.95.6(0.4)14.925.3Op cashflow growth (% YoY)(15.0)40.818.020.722.9Capex/sales (%)22.115.314.612.410.4Net debt/equity (%)29.628.621.015.88.3Net debt/Ebitda (x)1.31.21.00.60.3ROE (%)25.623.021.422.024.4	Intangible assets Other non-current assets Total assets Short-term debt Accounts payable Other current liabs Long-term debt/CBs Provisions/other LT liabs Shareholder funds Minorities/other equity Total liabs & equity Ratio analysis	4,416 3,497 1,532 30,305 2,068 923 2,166 6,399 443 18,237 69 30,305 2017A	4,724 3,812 1,906 <b>32,679</b> 3,094 920 2,588 6,875 499 18,625 78 <b>32,679</b> <b>2018A</b>	14,635 4,309 3,727 1,906 <b>34,278</b> 2,898 1,007 2,588 6,437 499 20,770 78 <b>34,278</b> <b>2019CL</b>	(8.8) (2.2) 0 4.9 (6.4) 9.5 0 (6.4) 0 11.5 0 4.9	16,119 4,309 3,644 1,906 <b>37,052</b> 2,948 1,156 2,588 6,549 499 23,234 78 <b>37,052</b> <b>2020CL</b>	17,542 4,309 3,562 1,906 <b>39,732</b> 2,773 1,306 2,588 6,162 499 26,326 78 <b>39,732</b> <b>2021CL</b>
Net profit growth (%)24.95.6(0.4)14.925.1Op cashflow growth (% YoY)(15.0)40.818.020.722.1Capex/sales (%)22.115.314.612.410.4Net debt/equity (%)29.628.621.015.88.1Net debt/Ebitda (x)1.31.21.00.60.1ROE (%)25.623.021.422.024.4	Intangible assets Other non-current assets Total assets Short-term debt Accounts payable Other current liabs Long-term debt/CBs Provisions/other LT liabs Shareholder funds Minorities/other equity Total liabs & equity Ratio analysis Revenue growth (% YoY)	4,416 3,497 1,532 30,305 2,068 923 2,166 6,399 443 18,237 69 30,305 2017A 14.6	4,724 3,812 1,906 <b>32,679</b> 3,094 920 2,588 6,875 499 18,625 78 <b>32,679</b> <b>2018A</b> 8.7	14,635 4,309 3,727 1,906 <b>34,278</b> 2,898 1,007 2,588 6,437 499 20,770 78 <b>34,278</b> <b>2019CL</b> 7.3	(8.8) (2.2) 0 4.9 (6.4) 9.5 0 (6.4) 0 11.5 0 4.9	16,119 4,309 3,644 1,906 <b>37,052</b> 2,948 1,156 2,588 6,549 499 23,234 78 <b>37,052</b> <b>2020CL</b> 17.4	17,542 4,309 3,562 1,906 <b>39,732</b> 2,773 1,306 2,588 6,162 499 26,326 78 <b>39,732</b> <b>2021CL</b> 14.3
Op cashflow growth (% YoY)(15.0)40.818.020.722.0Capex/sales (%)22.115.314.612.410.0Net debt/equity (%)29.628.621.015.88.0Net debt/Ebitda (x)1.31.21.00.60.0ROE (%)25.623.021.422.024.0	Intangible assets Other non-current assets Total assets Short-term debt Accounts payable Other current liabs Long-term debt/CBs Provisions/other LT liabs Shareholder funds Minorities/other equity Total liabs & equity Ratio analysis Revenue growth (% YoY) Ebitda margin (%)	4,416 3,497 1,532 30,305 2,068 923 2,166 6,399 443 18,237 69 30,305 2017A 14.6 29.3	4,724 3,812 1,906 <b>32,679</b> 3,094 920 2,588 6,875 499 18,625 78 <b>32,679</b> <b>2018A</b> 8.7 27.9	14,635 4,309 3,727 1,906 <b>34,278</b> 2,898 1,007 2,588 6,437 499 20,770 78 <b>34,278</b> <b>2019CL</b> 7.3 26.5	(8.8) (2.2) 0 4.9 (6.4) 9.5 0 (6.4) 0 11.5 0 4.9	16,119 4,309 3,644 1,906 <b>37,052</b> 2,948 1,156 2,588 6,549 499 23,234 78 <b>37,052</b> <b>2020CL</b> 17.4 28.4	17,542 4,309 3,562 1,906 <b>39,732</b> 2,773 1,306 2,588 6,162 499 26,326 78 <b>39,732</b> <b>2021CL</b> 14.3 29,9
Capex/sales (%)22.115.314.612.410.8Net debt/equity (%)29.628.621.015.88.1Net debt/Ebitda (x)1.31.21.00.60.3ROE (%)25.623.021.422.024.6	Intangible assets Other non-current assets Total assets Short-term debt Accounts payable Other current liabs Long-term debt/CBs Provisions/other LT liabs Shareholder funds Minorities/other equity Total liabs & equity Ratio analysis Revenue growth (% YoY) Ebitda margin (%)	4,416 3,497 1,532 30,305 2,068 923 2,166 6,399 443 18,237 69 30,305 2017A 14.6 29,3 23.1	4,724 3,812 1,906 <b>32,679</b> 3,094 920 2,588 6,875 499 18,625 78 <b>32,679</b> <b>2018A</b> 8.7 27.9 21.7	14,635 4,309 3,727 1,906 <b>34,278</b> 2,898 1,007 2,588 6,437 499 20,770 78 <b>34,278</b> <b>2019CL</b> 7.3 26.5 20.5	(8.8) (2.2) 0 4.9 (6.4) 9.5 0 (6.4) 0 11.5 0 4.9	16,119 4,309 3,644 1,906 <b>37,052</b> 2,948 1,156 2,588 6,549 499 23,234 78 <b>37,052</b> <b>2020CL</b> 17.4 28.4 23.0	17,542 4,309 3,562 1,906 <b>39,732</b> 2,773 1,306 2,588 6,162 499 26,326 78 <b>39,732</b> <b>2021CL</b> 14.3 29,9 24,9
Net debt/equity (%)         29.6         28.6         21.0         15.8         8.7           Net debt/Ebitda (x)         1.3         1.2         1.0         0.6         0.3           ROE (%)         25.6         23.0         21.4         22.0         24.0	Intangible assets Other non-current assets <b>Total assets</b> Short-term debt Accounts payable Other current liabs Long-term debt/CBs Provisions/other LT liabs Shareholder funds Minorities/other equity <b>Total liabs &amp; equity</b> <b>Ratio analysis</b> Revenue growth (% YoY) Ebitda margin (%) Ebit margin (%)	4,416 3,497 1,532 30,305 2,068 923 2,166 6,399 443 18,237 69 30,305 2017A 14.6 29,3 23.1 24.9	4,724 3,812 1,906 <b>32,679</b> 3,094 920 2,588 6,875 499 18,625 78 <b>32,679</b> <b>2018A</b> 8.7 27.9 21.7 5.6	14,635 4,309 3,727 1,906 <b>34,278</b> 2,898 1,007 2,588 6,437 499 20,770 78 <b>34,278</b> <b>2019CL</b> 7.3 26.5 20.5 (0.4)	(8.8) (2.2) 0 4.9 (6.4) 9.5 0 (6.4) 0 11.5 0 4.9	16,119 4,309 3,644 1,906 <b>37,052</b> 2,948 1,156 2,588 6,549 499 23,234 78 <b>37,052</b> <b>2020CL</b> 17.4 28.4 23.0 14.9	17,542 4,309 3,562 1,906 <b>39,732</b> 2,773 1,306 2,588 6,162 499 26,326 78 <b>39,732</b> <b>2021CL</b> 14.3 29,9 24,9 25,5
Net debt/Ebitda (x)         1.3         1.2         1.0         0.6         0.3           ROE (%)         25.6         23.0         21.4         22.0         24.0	Intangible assets Other non-current assets <b>Total assets</b> Short-term debt Accounts payable Other current liabs Long-term debt/CBs Provisions/other LT liabs Shareholder funds Minorities/other equity <b>Total liabs &amp; equity</b> <b>Ratio analysis</b> Revenue growth (% YoY) Ebitda margin (%) Ebit margin (%) Net profit growth (% YoY)	4,416 3,497 1,532 <b>30,305</b> 2,068 923 2,166 6,399 443 18,237 69 <b>30,305</b> <b>2017A</b> 14.6 29,3 23,1 24.9 (15.0)	4,724 3,812 1,906 <b>32,679</b> 3,094 920 2,588 6,875 499 18,625 78 <b>32,679</b> <b>2018A</b> 8.7 27.9 21.7 5.6 40.8	14,635 4,309 3,727 1,906 <b>34,278</b> 2,898 1,007 2,588 6,437 499 20,770 78 <b>34,278</b> <b>2019CL</b> 7.3 26.5 20.5 (0.4) 18.0	(8.8) (2.2) 0 4.9 (6.4) 9.5 0 (6.4) 0 11.5 0 4.9	16,119 4,309 3,644 1,906 <b>37,052</b> 2,948 1,156 2,588 6,549 499 23,234 78 <b>37,052</b> <b>2020CL</b> 17.4 28.4 23.0 14.9 20.7	17,542 4,309 3,562 1,906 <b>39,732</b> 2,773 1,306 2,588 6,162 499 26,326 78 <b>39,732</b> <b>2021CL</b> 14.3 29,9 24,9 24,9 25,5 22,9
ROE (%) 25.6 23.0 21.4 22.0 24.0	Intangible assets Other non-current assets <b>Total assets</b> Short-term debt Accounts payable Other current liabs Long-term debt/CBs Provisions/other LT liabs Shareholder funds Minorities/other equity <b>Total liabs &amp; equity</b> <b>Ratio analysis</b> Revenue growth (% YoY) Ebitda margin (%) Ebit margin (%) Net profit growth (% YoY) Capex/sales (%)	4,416 3,497 1,532 <b>30,305</b> 2,068 923 2,166 6,399 443 18,237 69 <b>30,305</b> <b>2017A</b> 14,6 29,3 23,1 24,9 (15,0) 22,1	4,724 3,812 1,906 <b>32,679</b> 3,094 920 2,588 6,875 499 18,625 78 <b>32,679</b> <b>2018A</b> 8.7 27.9 21.7 5.6 40.8 15.3	14,635 4,309 3,727 1,906 <b>34,278</b> 2,898 1,007 2,588 6,437 499 20,770 78 <b>34,278</b> <b>2019CL</b> 7.3 26.5 20.5 (0.4) 18.0 14.6	(8.8) (2.2) 0 4.9 (6.4) 9.5 0 (6.4) 0 11.5 0 4.9	16,119 4,309 3,644 1,906 <b>37,052</b> 2,948 1,156 2,588 6,549 499 23,234 78 <b>37,052</b> <b>2020CL</b> 17.4 28.4 23.0 14.9 20.7 12.4	17,542 4,309 3,562 1,906 <b>39,732</b> 2,773 1,306 2,588 6,162 499 26,326 78 <b>39,732</b> <b>2021CL</b> 14.3 29.9 24.9 24.9 25.5 22.9 10.8
	Intangible assets Other non-current assets <b>Total assets</b> Short-term debt Accounts payable Other current liabs Long-term debt/CBs Provisions/other LT liabs Shareholder funds Minorities/other equity <b>Total liabs &amp; equity</b> <b>Ratio analysis</b> Revenue growth (% YoY) Ebitda margin (%) Ebit margin (%) Net profit growth (% YoY) Capex/sales (%) Net debt/equity (%)	4,416 3,497 1,532 <b>30,305</b> 2,068 923 2,166 6,399 443 18,237 69 <b>30,305</b> <b>2017A</b> 14,6 29,3 23,1 24,9 (15,0) 22,1 29,6	4,724 3,812 1,906 <b>32,679</b> 3,094 920 2,588 6,875 499 18,625 78 <b>32,679</b> <b>2018A</b> 8.7 27.9 21.7 5.6 40.8 15.3 28.6	14,635 4,309 3,727 1,906 <b>34,278</b> 2,898 1,007 2,588 6,437 499 20,770 78 <b>34,278</b> <b>2019CL</b> 7.3 26.5 20.5 (0.4) 18.0 14.6 21.0	(8.8) (2.2) 0 4.9 (6.4) 9.5 0 (6.4) 0 11.5 0 4.9	16,119 4,309 3,644 1,906 <b>37,052</b> 2,948 1,156 2,588 6,549 499 23,234 78 <b>37,052</b> <b>2020CL</b> 17.4 28.4 23.0 14.9 20.7 12.4 15.8	17,542 4,309 3,562 1,906 <b>39,732</b> 2,773 1,306 2,588 6,162 499 26,326 78 <b>39,732</b> <b>2021CL</b> 14.3 29.9 24.9 24.9 25.5 22.9 10.8 8.7
ROIC (%) 16.6 15.0 14.5 17.3 20.0	Intangible assets Other non-current assets <b>Total assets</b> Short-term debt Accounts payable Other current liabs Long-term debt/CBs Provisions/other LT liabs Shareholder funds Minorities/other equity <b>Total liabs &amp; equity</b> <b>Ratio analysis</b> Revenue growth (% YoY) Ebitda margin (%) Ebit margin (%) Net profit growth (% YoY) Capex/sales (%) Net debt/equity (%) Net debt/Ebitda (x)	4,416 3,497 1,532 <b>30,305</b> 2,068 923 2,166 6,399 443 18,237 69 <b>30,305</b> <b>2017A</b> 14,6 29,3 23,1 24,9 (15,0) 22,1 29,6 1,3	4,724 3,812 1,906 <b>32,679</b> 3,094 920 2,588 6,875 499 18,625 78 <b>32,679</b> <b>2018A</b> 8.7 27.9 21.7 5.6 40.8 15.3 28.6 1.2	14,635 4,309 3,727 1,906 <b>34,278</b> 2,898 1,007 2,588 6,437 499 20,770 78 <b>34,278</b> <b>2019CL</b> 7.3 26.5 20.5 (0.4) 18.0 14.6 21.0 1.0	(8.8) (2.2) 0 4.9 (6.4) 9.5 0 (6.4) 0 11.5 0 4.9	16,119 4,309 3,644 1,906 <b>37,052</b> 2,948 1,156 2,588 6,549 499 23,234 78 <b>37,052</b> <b>2020CL</b> 17.4 28.4 23.0 14.9 20.7 12.4 15.8 0.6	17,542 4,309 3,562 1,906 <b>39,732</b> 2,773 1,306 2,588 6,162 499 26,326 78 <b>39,732</b> <b>2021CL</b> 14.3 29.9 24.9 24.9 25.5 22.9 10.8

Source: www.clsa.com

Find CLSA research on Bloomberg, Thomson Reuters, Factset and CapitalIQ - and profit from our evalu@tor proprietary database at clsa.com

## Short-selling report arguments and our quick view Dividends

Argument 1: Xinyi Glass never remitted cash from China to Hong Kong for the payment of dividends, but financed such with Hong Kong dollar debt, and thus is unable to verify profit.

**Our quick view:** We do not rule out that the company's Hong Kong dollar financing is to partly to fund its dividend payment, but not necessarily all dividend payments are funded by debt. Funding dividends by borrowing does not mean it is wrong or fraudulent. We see the key reason for this as the cost of financing, which is around 2% as the company borrows in Hong Kong versus the withholding the tax required to pay for remitting cash outside China for dividends, which is 5%. The cost difference is already a strong argument for the move. We believe investors would prefer the dividend payout to remain steady instead of cutting the dividend in order to save interest or tax costs.

Xinyi Glass is also generating operating cash inflow in terms of foreign currency, given that it has close to c.30% of its revenue from overseas. Its operating cash flow should also be able to fund its dividend payments, thus it is not necessary all dividend payments are funded in Hong Kong dollar debt.

Also note the company has started overseas expansion, currently in Malaysia and potentially in other Southeast Asian countries, the Middle-east and Canada. Thus, it can also be the case the company funds its dividend payment with its foreign currency cashflow and funds its overseas Capex with borrowing.

Figure 1 Xinyi Glass: debt versus interest expenses					
· · ·					
HK\$m	2014	2015	2016	2017	2018
Total Debt	6,013	6,028	7,674	8,466	9,969
Interest Expense	91	90	128	151	214
Avg Interest Rate	1.6%	1.5%	1.9%	1.9%	2.3%
Dividend payment					
- Final dividend in the prior year	549	235	657	962	1,125
- Interim dividend in the current year	353	373	661	801	999
Total dividend payment in cash	902	608	1,317	1,762	2,124

Figure 2

HK\$m	2014	2015	2016	2017	2018
Overseas revenue	3,218	3,402	3,429	3,953	4,577
As % of overall revenue	29.6%	29.7%	26.7%	26.8%	28.6%
Dividend payment					
- Final dividend in the prior year	549	235	657	962	1,125
- Interim dividend in the current year	353	373	661	801	999
Total dividend payment in cash	902	608	1,317	1,762	2,124
Total dividend payment in cash as % of overseas revenue of the year	28.0%	17.9%	38.4%	44.6%	46.4%

On the other hand, Xinyi Glass made an announcement (*link*) after its 2015 results that it will pay its 2015 final dividend would be declared by deducting its share premium account, which was accumulated by the previous equity fund raising activities in Hong Kong and was in Hong Kong dollar. Thus, the payment of dividend in Hong Kong dollar instead of remitting cash out from China should have been well known.

#### **OP** margin and the build-up of cash

Argument 2: Signals of fraud and fake cash flow include its super-normal profitability relative peers (e.g. its OPM higher than peers like Fuyao Glass Industry Group Co Ltd.), and it has seen a build-up of non-production assets (mainly onshore cash).

**Our quick view:** It true Xinyi Glass has a higher-than-peer OPM, but this is explainable.

Figure 3 compares Xinyi Glass's OPM (including and excluding other gains like FX and fair value changes) with that of Fuyao Glass (3606.HK). Xinyi Glass has a higher OPM than Fuyao. One reason is that Xinyi Glass has an integrated business model and thus its in-house float glass supply provides more than enough for self-production uses. Fuyao, on the other hand, has in-house float glass supplying only for c.80% of its production needs, thus still need to purchase float glass externally. Fuyao has been ramping-up its auto glass production base in the US since 2016, which still has a lower margin than its Chinese production base, and thus this has been a drag on its overall margin performance as well.

We also compare Xinyi Glass's margin with that of Kibing (601636.CH), another leading float glass player in China. Xinyi Glass has a higher margin than Kibing given Kibing mainly sells lower-margin float glass and a small portion of architecture glass, but Xinyi Glass has a contribution from higher-margin auto glass sales.

<b>2014</b> 13.8% 11.7%	<b>2015</b> 18.4%	<b>2016</b> 26.0%	<b>2017</b> 27.9%	<b>2018</b> 28.4%
		26.0%	27.9%	28.4%
		26.0%	27.9%	28.4%
11.7%				20.470
	15.1%	24.7%	25.7%	25.0%
21.9%	23.6%	23.9%	19.8%	25.2%
22.3%	20.9%	20.9%	21.9%	20.2%
9.8%	8.2%	17.5%	19.1%	16.3%
	21.9% 22.3%	21.9%     23.6%       22.3%     20.9%	21.9%     23.6%     23.9%       22.3%     20.9%     20.9%	21.9%       23.6%       23.9%       19.8%         22.3%       20.9%       20.9%       21.9%

## Figure 3

Source: Respective companies, CLSA

Besides, the improvement in Xinyi Glass's margin in 2016-2018 vs 2014-2015 was due to improvement in the float glass industry from its trough in 2014-2015, and saw Xinyi Glass significantly increase its production scale in 2014-2015 with new bases in Sichuan and Yingkou which started to yield fruit when the market recovered. Its capacity growth then slowed afterwards given the limitations of new production line permits in China, and thus the company shifted its expansion focus overseas. This explains the reason behind why its cash level (due to increasing operating cashflow relative to Capex) increased faster than that of sales, i.e. a rising cash to sales ratio, especially from onshore cash, in our view.







Figure 6

2014	2015	2016	2017	2018
1,455	2,637	3,565	3,535	4,643
(1,729)	(1,967)	(1,853)	(3,254)	(2,453)
4,234	4,251	4,900	5,290	5,400
20%	0%	15%	8%	2%
(274)	670	1,712	281	2,190
832	1,300	2,768	3,051	4,613
10,861	11,460	12,848	14,728	16,014
7.7%	11.3%	21.5%	20.7%	28.8%
	1,455 (1,729) 4,234 20% (274) 832 10,861	1,455     2,637       (1,729)     (1,967)       4,234     4,251       20%     0%       (274)     670       832     1,300       10,861     11,460	1,455         2,637         3,565           (1,729)         (1,967)         (1,853)           4,234         4,251         4,900           20%         0%         15%           (274)         670         1,712           832         1,300         2,768           10,861	1,455         2,637         3,565         3,535           (1,729)         (1,967)         (1,853)         (3,254)           4,234         4,251         4,900         5,290           20%         0%         15%         8%           (274)         670         1,712         281           832         1,300         2,768         3,051

#### Tax

Argument 3: it is unable to verify Xinyi Glass's profit from the tax breakdown as it was not remitting profit to Hong Kong for dividend payments. Its Hong Kong business margin appeared to have dropped, but it did not recognise enough profit in Hong Kong to cover expenses like overhead and interest.

**Our quick view:** We have argued that funding of dividend payment by Hong Kong dollar debt is not wrong. The apparent drop in profit from Hong Kong, as shown by the reduced HK profit tax, could be a result of the increase in expenses in Hong Kong(including interest expenses and other corporate expenses), not necessary the Company not recognizing enough profit in Hong Kong to cover such expenses. Note that this could also be a result of tax planning, given that 13 of the companies' subsidiaries in China enjoys high-tech enterprise income tax benefit with preferential tax rate of 15%, compared with the 16.5% corporate income tax rate in Hong Kong.

Xinyi Glass – Income tax expenses breakdown					
	2014	2015	2016	2017	2018
Current income tax					
<ul> <li>Hong Kong profits tax</li> </ul>	23	47	36	17	15
– PRC corporate income tax	208	226	513	544	621
- Overseas income tax	1	0	(0)	1	0
- (Over)/under provision in prior years	(3)	(7)	(1)	9	(3)
Deferred income tax	(0)	(0)	59	111	90
Total	228	266	607	682	723

Source: Company, CLSA

Figure 7

#### **Offshore asset sales**

Argument 4: The recent decent disposal of Xinyi Solar Holdings is not necessary given its strong cash on hand.

**Our quick view:** In our last report *China/HK SMID caps* (*Glass: Xinyi Glass offloads XYS*) on 18 June 2019, we had been expecting Xinyi Glass could use the proceeds for the purposes paying dividend (particularly that the capital gain could boost reported profit and be included in its dividend calculation—and again this is not wrong) or making other investments (mainly overseas as explained above). The market should have known about this as well. Note that Xinyi Glass earlier subscribed a 5.9% stake in Xinyi Energy (3868.HK) in the spin-off, at a total consideration of HK\$763m, thus the disposal of Xinyi Solar Holdings could also help replenish some of its Hong Kong dollar cash.

#### Depreciation

Argument 5: Xinyi Glass extended the depreciation life of plant and machinery from 5-15 years to 5-20 in 2015. Subsequent continuous losses on the disposal of plant and machinery suggest its depreciation schedule was not conservative enough.

**Our quick view:** The extension in the depreciation life of plant and machinery from 5-15 years to 5-20 years was due to investment in its roof-top solar farm, which has an operating life of 20 years (as specified by the Golden Sun subsidy program in China). Besides, the losses on the disposal of plant and machinery in 2015-2018 were just 1.4%-3.4% of the net book amount of the plant and machinery in the prior year-end, or just 0.1%-0.3% of the depreciation expenses of the prior year-end, which are immaterial in our view.

Figure 8

	2014	2015	2016	2017	2018
Depreciation expense	643	749	819	971	993
- In which: Plant and machinery	537	632	685	790	813
Year-end net book amount of plant and machinery	7,093	8,374	7,870	9,239	8,923
Gain/(losses) on disposal of property, plant and equipment	109	(18)	(11)	(17)	(11)
Gain/(losses) on disposal as % of depreciation of previous year		-3.4%	-1.7%	-2.5%	-1.4%
Gain/(losses) on disposal as % of net book amount of previous year		-0.3%	-0.1%	-0.2%	-0.1%

### **Incentive for fraud**

Argument 6: There was the incentive for fraud as the HK\$732m convertible bond was due by May 2017, but the company only had HK\$832m cash on hand by end-2014.

**Our quick view:** 2014 was well-known to be the trough of the float glass industry, but it also started to stabilise and improve in late-2015. The float glass cycle used to last for 1-2 years, thus we do not see any incentive for the company to manipulate its earnings for several years. Besides, Xinyi Glass's net gearing by end-2014 was 42%, which was not excessive, thus the company could consider raise more borrowing to refund the convertible bond instead of manipulating profit as suggested by the short-selling report.

## We reiterate our positive stance

We see these arguments as weak in general; we thus reiterate our positive stance on Xinyi Glass amid recent market capacity reductions, a potential demand pick-up in 2H19, plus capacity expansion to fuel long-term growth momentum. Our target price is unchanged at HK\$10.90, which is based on a blend of PE and PB. At a 9.0x 19CL PE with a 6.3% 19CL dividend yield we retain our BUY recommendation on Xinyi Glass.

Xinyi Glass earnings revisions									
HK\$m		New			Old			Change	
	19CL	20CL	21CL	19CL	20CL	21CL	19CL	20CL	21CL
Revenue									
Automobile glass products	4,495	5,046	5,167	4,495	5,046	5,167	0.0%	0.0%	0.0%
Architecture glass	3,717	4,065	4,689	3,717	4,065	4,689	0.0%	0.0%	0.0%
Float glass (including electronic glass)	8,969	11,055	13,196	8,969	11,055	13,196	0.0%	0.0%	0.0%
Total	17,181	20,167	23,052	17,181	20,167	23,052	0.0%	0.0%	0.0%
Gross margin									
Automobile glass products	44.6%	45.6%	46.1%	44.6%	45.6%	46.1%	0.0 ppt	0.0 ppt	0.0 ppt
Architecture glass	39.0%	40.2%	41.2%	39.0%	40.2%	41.2%	0.0 ppt	0.0 ppt	0.0 ppt
Float glass (including electronic glass)	30.1%	32.9%	34.8%	30.1%	32.9%	34.8%	0.0 ppt	0.0 ppt	0.0 ppt
Total	35.8%	37.6%	38.6%	35.8%	37.6%	38.6%	0.0 ppt	0.0 ppt	0.0 ppt
Core profit	3,704	4,851	6,086	3,704	4,851	6,086	0.0%	0.0%	0.0%



	Figure 10	
Its earnings are more	Earnings sensitivity analysis	
sensitive to prices than		Change in 19CL core profit
costs	1% increase in float glass price	+1.6%
	1% increase in auto glass price	+0.8%
	1% increase in architecture glass price	+0.7%
	1% increase in soda ash price	-0.5%
	1% increase in unit fuel cost	-0.7%
	Source: CLSA	
	Figure 11	
Our target price is based on	Valuation of Xinyi Glass	
a blended PE and PB	PE basis	
approach	20CL EPS (HK\$)	1.20
	Target multiple (x)	9.
	Fair value (HK\$)	11.40
	PB basis	
	19CL BVPS (HK\$)	5.1
	Target multiple (x)	2.0
	Fair value (HK\$)	10.30
	Average (HK\$)	10.90
	Implying 19/20CL PE	11.9x/9.1
	Source: CLSA	
igure 12	Figure 13	





Source: CLSA, Datastream

### Valuation details

We value XYG using a blended PE and PB approach. We apply a target multiple of 9.5.x to 20CL EPS and a target multiple of 2.0x to 19CL BVPS, around 0.5SD above historical averages.

#### **Investment risks**

Key risks include: 1) Weakening of the property market or even the auto market. Demand for float glass and construction glass is highly dependent on the property market. Besides, despite being a stable business, the auto glass segment is correlated to the global number of vehicles in use, and any significant slowdown in the global auto industry may also affect the segment's performance. 2) Further tightening of credit. Tightening of credit also affects developers' cash flows and progress in construction of property projects. 3) Incremental production costs. A significant surge in natural gas, international crude oil prices and other raw material costs may affect XYG's gross margin if it cannot pass on incremental costs by raising ASP. 4) More capacity additions in the market.



# **Detailed financials**

Profit & Loss (HK\$m)							
Year to 31 December	2015A	2016A	2017A	2018A	2019CL	2020CL	2021CL
Revenue	11,460	12,848	14,728	16,014	17,181	20,167	23,052
Cogs (ex-D&A)	(7,564)	(7,392)	(8,438)	(9,222)	(10,085)	(11,575)	(13,070)
Gross Profit (ex-D&A)	3,896	5,456	6,290	6,792	7,096	8,592	9,982
Research & development costs	-	-	-	-	-	-	-
Selling & marketing expenses	-	-	-	-	-	-	-
Other SG&A	(1,583)	(1,793)	(1,970)	(2,320)	(2,544)	(2,860)	(3,084)
Other Op Expenses ex-D&A	-	-	-	0	-	-	-
Op Ebitda	2,313	3,664	4,320	4,472	4,552	5,732	6,898
Depreciation/amortisation	(795)	(827)	(921)	(1,004)	(1,030)	(1,099)	(1,158)
Op Ebit	1,518	2,837	3,399	3,468	3,523	4,633	5,739
Interest income	40	51	45	71	89	100	116
Interest expense	(90)	(128)	(151)	(214)	(225)	(218)	(213)
Net interest inc/(exp)	(50)	(77)	(107)	(142)	(136)	(118)	(97)
Associates/investments	317	563	700	566	481	630	870
Forex/other income	-	-	-	-	-	-	-
Asset sales/other cash items	215	342	387	541	589	682	771
Provisions/other non-cash items	-	-	-	-	-	-	-
Asset revaluation/Exceptional items	379	159	317	537	518	-	-
Profit before tax	2,380	3,823	4,696	4,970	4,975	5,826	7,283
Taxation	(266)	(607)	(682)	(723)	(742)	(965)	(1,187)
Profit after tax	2,114	3,216	4,014	4,248	4,233	4,861	6,096
Preference dividends	0	0	0	0	0	0	0
Profit for period	2,114	3,216	4,014	4,248	4,233	4,861	6,096
Minority interest	0	(3)	0	(11)	(11)	(11)	(11)
Net profit	2,113	3,213	4,014	4,237	4,222	4,851	6,086
Extraordinaries/others	0	0	0	0	0	0	0
Profit avail to ordinary shares	2,113	3,213	4,014	4,237	4,222	4,851	6,086
Dividends	(1,029)	(1,622)	(1,926)	(2,078)	(2,077)	(2,386)	(2,994)
Retained profit	1,084	1,591	2,088	2,159	2,145	2,464	3,092
Adjusted profit	1,734	3,055	3,697	3,699	3,704	4,851	6,086
EPS (HK¢)	52.4	80.5	99.7	105.0	104.6	120.2	150.8
Adj EPS [pre excep] (HK¢)	43.0	76.5	91.9	91.7	91.8	120.2	150.8
Core EPS (HK¢)	43.0	76.5	91.9	91.7	91.8	120.2	150.8
DPS (HK¢)	26.5	40.0	48.0	52.0	51.8	59.5	74.7

## **Profit & loss ratios**

Year to 31 December	2015A	2016A	2017A	2018A	2019CL	2020CL	2021CL
Growth (%)							
Revenue growth (% YoY)	5.5	12.1	14.6	8.7	7.3	17.4	14.3
Ebitda growth (% YoY)	33.0	58.4	17.9	3.5	1.8	25.9	20.3
Ebit growth (% YoY)	38.6	86.9	19.8	2.0	1.6	31.5	23.9
Net profit growth (%)	55.0	52.1	24.9	5.6	(0.4)	14.9	25.5
EPS growth (% YoY)	55.1	53.5	23.9	5.3	(0.3)	14.9	25.5
Adj EPS growth (% YoY)	51.7	77.8	20.1	(0.2)	0.1	31.0	25.5
DPS growth (% YoY)	76.7	50.9	20.0	8.3	(0.3)	14.9	25.5
Core EPS growth (% YoY)	51.7	77.8	20.1	(0.2)	0.1	31.0	25.5
Margins (%)							
Ebitda margin (%)	20.2	28.5	29.3	27.9	26.5	28.4	29.9
Ebit margin (%)	13.2	22.1	23.1	21.7	20.5	23.0	24.9
Net profit margin (%)	18.4	25.0	27.3	26.5	24.6	24.1	26.4
Core profit margin	15.1	23.8	25.1	23.1	21.6	24.1	26.4
Op cashflow margin	14.7	19.1	14.2	18.3	20.2	20.7	22.3
Returns (%)							
ROE (%)	16.9	24.8	25.6	23.0	21.4	22.0	24.6
ROA (%)	6.4	10.5	10.7	9.4	9.0	10.8	12.5
ROIC (%)	8.7	15.7	16.6	15.0	14.5	17.3	20.0
ROCE (%)	8.7	15.9	16.2	14.5	14.3	17.7	20.6
Other key ratios (%)							
Effective tax rate (%)	11.2	15.9	14.5	14.5	14.9	16.6	16.3
Ebitda/net int exp (x)	46.1	47.7	40.6	31.4	33.4	48.4	71.0
Exceptional or extraord. inc/PBT (%)	15.9	4.2	6.7	10.8	10.4	0.0	0.0
Dividend payout (%)	50.5	49.7	48.1	49.5	49.5	49.5	49.5

Source: www.clsa.com



## Balance sheet (HK\$m)

Year to 31 December	2015A	2016A	2017A	2018A	2019CL	2020CL	2021CL
Cash & equivalents	1,300	2,768	3,051	4,613	4,949	5,809	6,640
Accounts receivable	1,136	1,036	1,243	1,278	1,352	1,587	1,814
Inventories	1,223	1,321	1,698	1,755	1,887	2,166	2,446
Other current assets	1,337	1,412	1,940	1,513	1,513	1,513	1,513
Current assets	4,995	6,537	7,932	9,158	9,701	11,075	12,414
Fixed assets	11,971	11,831	12,929	13,079	14,635	16,119	17,542
Investments	2,535	3,258	4,416	4,724	4,309	4,309	4,309
Goodwill	0	0	0	0	0	0	0
Other intangible assets	1,281	1,193	3,497	3,812	3,727	3,644	3,562
Other non-current assets	639	1,205	1,532	1,906	1,906	1,906	1,906
Total assets	21,422	24,022	30,305	32,679	34,278	37,052	39,732
Short term loans/OD	2,514	3,165	2,068	3,094	2,898	2,948	2,773
Accounts payable	740	789	923	920	1,007	1,156	1,306
Accrued expenses	-	-	-	-	-	-	-
Taxes payable	333	538	535	611	611	611	611
Other current liabs	1,373	1,508	1,631	1,977	1,977	1,977	1,977
Current liabilities	4,959	6,000	5,157	6,603	6,493	6,692	6,668
Long-term debt/leases/other	3,514	4,509	6,399	6,875	6,437	6,549	6,162
Convertible bonds	0	0	0	0	0	0	0
Provisions/other LT liabs	223	266	443	499	499	499	499
Total liabilities	8,696	10,775	11,999	13,977	13,430	13,741	13,329
Share capital	4,278	1,719	3,038	1,587	1,587	1,587	1,587
Retained earnings	8,441	11,462	15,199	17,037	19,182	21,647	24,739
Reserves/others	0	-	0	0	0	0	-
Shareholder funds	12,718	13,181	18,237	18,625	20,770	23,234	26,326
Minorities/other equity	7	66	69	78	78	78	78
Total equity	12,726	13,247	18,306	18,702	20,847	23,312	26,404
Total liabs & equity	21,422	24,022	30,305	32,679	34,278	37,052	39,732
Total debt	6,028	7,674	8,466	9,969	9,335	9,497	8,935
Net debt	4,729	4,906	5,415	5,357	4,386	3,688	2,295
Adjusted EV	34,517	33,789	34,337	33,960	33,398	32,700	31,307
BVPS (HK¢)	324.3	338.6	451.7	461.6	514.8	575.9	652.5

## **Balance sheet ratios**

Dalance sheet ratios							
Year to 31 December	2015A	2016A	2017A	2018A	2019CL	2020CL	2021CL
Key ratios							
Current ratio (x)	1.0	1.1	1.5	1.4	1.5	1.7	1.9
Growth in total assets (% YoY)	1.8	12.1	26.2	7.8	4.9	8.1	7.2
Growth in capital employed (% YoY)	(0.4)	4.0	30.7	1.4	4.9	7.0	6.3
Net debt to operating cashflow (x)	2.8	2.0	2.6	1.8	1.3	0.9	0.4
Gross debt to operating cashflow (x)	3.6	3.1	4.1	3.4	2.7	2.3	1.7
Gross debt to Ebitda (x)	2.6	2.1	2.0	2.2	2.1	1.7	1.3
Net debt/Ebitda (x)	2.0	1.3	1.3	1.2	1.0	0.6	0.3
Gearing							
Net debt/equity (%)	37.2	37.0	29.6	28.6	21.0	15.8	8.7
Gross debt/equity (%)	47.4	57.9	46.2	53.3	44.8	40.7	33.8
Interest cover (x)	17.3	22.6	22.8	16.6	16.1	21.7	27.5
Debt Cover (x)	0.3	0.3	0.2	0.3	0.4	0.4	0.6
Working capital analysis							
Inventory days	65.2	62.8	65.3	68.3	65.9	63.9	64.4
Debtor days	34.5	30.9	28.2	28.7	27.9	26.6	26.9
Creditor days	35.3	37.8	37.0	36.5	34.9	34.1	34.4
Working capital/Sales (%)	10.9	7.3	12.2	6.5	6.7	7.5	8.2
Capital employed analysis							
Sales/Capital employed (%)	65.7	70.8	62.1	66.6	68.1	74.7	80.3
EV/Capital employed (%)	197.8	186.1	144.8	141.2	132.4	121.1	109.1
Working capital/Capital employed (%)	7.2	5.1	7.6	4.3	4.6	5.6	6.5
Fixed capital/Capital employed (%)	68.6	65.2	54.5	54.4	58.0	59.7	61.1
Other ratios (%)							
EV/OCF (x)	20.5	13.8	16.5	11.6	9.6	7.8	6.1
EV/FCF (x)	(122.6)	56.3	(29.4)	70.0	34.6	19.4	11.9
EV/Sales (x)	3.0	2.6	2.3	2.1	1.9	1.6	1.4
Capex/depreciation (%)	257.6	232.5	384.8	267.5	264.6	246.1	232.1

Source: www.clsa.com



## Cashflow (HK\$m)

Year to 31 December	2015A	2016A	2017A	2018A	2019CL	2020CL	2021CL
Operating profit	1,518	2,837	3,399	3,468	3,523	4,633	5,739
Operating adjustments	-	-	-		-	-	-
Depreciation/amortisation	795	827	921	1,004	1,030	1,099	1,158
Working capital changes	(207)	(426)	(1,332)	(481)	(119)	(365)	(358)
Interest paid / other financial expenses	(155)	(177)	(219)	(330)	(225)	(218)	(213)
Tax paid	(266)	(607)	(682)	(723)	(742)	(965)	(1,187)
Other non-cash operating items	-	-	-	-	-	-	-
Net operating cashflow	1,685	2,453	2,086	2,938	3,466	4,183	5,140
Capital expenditure	(1,967)	(1,853)	(3,254)	(2,453)	(2,500)	(2,500)	(2,500)
Free cashflow	(282)	600	(1,168)	485	966	1,683	2,640
Acq/inv/disposals	-	-	-	-	415	-	-
Int, invt & associate div	951	1,112	1,448	1,705	1,666	1,401	1,746
Net investing cashflow	(1,016)	(741)	(1,806)	(748)	(419)	(1,099)	(754)
Increase in loans	16	1,646	792	1,503	(634)	162	(561)
Dividends	(1,029)	(1,622)	(1,926)	(2,078)	(2,077)	(2,386)	(2,994)
Net equity raised/(buybacks)	-	-	-		-	-	-
Net financing cashflow	(202)	(244)	2	(628)	(2,711)	(2,225)	(3,555)
Incr/(decr) in net cash	468	1,468	283	1,562	336	860	831
Exch rate movements	-	-	-		-	-	-
Opening cash	832	1,300	2,768	3,051	4,613	4,949	5,809
Closing cash	1,300	2,768	3,051	4,613	4,949	5,809	6,640
OCF PS (HK¢)	41.8	61.4	51.8	72.8	85.9	103.7	127.4
FCF PS (HK¢)	(7.0)	15.0	(29.0)	12.0	23.9	41.7	65.4

## **Cashflow ratio analysis**

Year to 31 December	2015A	2016A	2017A	2018A	2019CL	2020CL	2021CL
Growth (%)							
Op cashflow growth (% YoY)	94.3	45.6	(15.0)	40.8	18.0	20.7	22.9
FCF growth (% YoY)	-	-	(294.4)	-	99.1	74.3	56.8
Capex growth (%)	13.8	(5.8)	75.6	(24.6)	1.9	0.0	0.0
Other key ratios (%)							
Capex/sales (%)	17.2	14.4	22.1	15.3	14.6	12.4	10.8
Capex/op cashflow (%)	116.7	75.5	156.0	83.5	72.1	59.8	48.6
Operating cashflow payout ratio (%)	63.4	65.1	92.6	71.4	60.3	57.4	58.6
Cashflow payout ratio (%)	61.1	66.1	92.3	70.7	59.9	57.0	58.2
Free cashflow payout ratio (%)	-	270.2	-	428.4	215.0	141.7	113.4

## **DuPont analysis**

Year to 31 December	2015A	2016A	2017A	2018A	2019CL	2020CL	2021CL
Ebit margin (%)	13.2	22.1	23.1	21.7	20.5	23.0	24.9
Asset turnover (x)	0.5	0.6	0.5	0.5	0.5	0.6	0.6
Interest burden (x)	1.6	1.3	1.4	1.4	1.4	1.3	1.3
Tax burden (x)	0.9	0.8	0.9	0.9	0.9	0.8	0.8
Return on assets (%)	6.4	10.5	10.7	9.4	9.0	10.8	12.5
Leverage (x)	1.7	1.7	1.7	1.7	1.7	1.6	1.5
ROE (%)	16.9	24.8	25.4	23.0	21.4	22.0	24.5

## EVA<sup>®</sup> analysis

Year to 31 December	2015A	2016A	2017A	2018A	2019CL	2020CL	2021CL
Ebit adj for tax	1,348	2,386	2,905	2,964	2,997	3,865	4,804
Average invested capital	15,415	15,152	17,455	19,792	20,629	22,307	24,040
ROIC (%)	8.7	15.7	16.6	15.0	14.5	17.3	20.0
Cost of equity (%)	14.3	14.3	14.3	14.3	14.3	14.3	14.3
Cost of debt (adj for tax)	1.4	1.4	1.4	1.4	1.4	1.4	1.4
Weighted average cost of capital (%)	10.6	10.6	10.6	10.6	10.6	10.6	10.6
EVA/IC (%)	(1.9)	5.1	6.0	4.4	3.9	6.7	9.4
EVA (HK\$m)	(290)	779	1,053	864	808	1,500	2,255

Source: www.clsa.com





**Research subscriptions** 

To change your report distribution requirements, please contact your CLSA sales representative or email us at cib@clsa.com. You can also fine-tune your Research Alert email preferences at https://www.clsa.com/member/tools/email\_alert/.

## **Companies mentioned**

Xinyi Glass (868 HK - HK\$8.24 - BUY) Fuyao Glass (3606 HK - HK\$23.80 - O-PF) Kibing (N-R) Xinyi Energy (3868.HK) (N-R) Xinyi Solar (968 HK - HK\$3.69 - BUY)

#### Analyst certification

The analyst(s) of this report hereby certify that the views expressed in this research report accurately reflect my/our own personal views about the securities and/or the issuers and that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation or views contained in this research report.

#### Important disclosures



Sep 16 Jan 17 May 17 Sep 17 Jan 18 May 18 Sep 18 Jan 19 May 19

Date	Rec	Target	Date	Rec	Target
23 May 2019	BUY	10.90	14 Dec 2017	BUY	10.70
26 Feb 2019	BUY	11.60	31 Oct 2017	BUY	9.50
03 Dec 2018	BUY	12.10	17 Jul 2017	BUY	9.60
31 Jul 2018	BUY	12.90	14 Dec 2016	BUY	8.35
27 Jun 2018	BUY	13.60	08 Nov 2016	BUY	8.30
01 May 2018	BUY	14.30	08 Sep 2016	BUY	8.35
27 Feb 2018	BUY	14.70	03 Aug 2016	BUY	7.25
24 Jan 2018	BUY	13.10			

Source: CLSA



Sep 16 Jan 17 May 17 Sep 17 Jan 18 May 18 Sep 18 Jan 19 May 19

Date	Rec	Target	Date	Rec	Target
18 Jun 2019	BUY	4.80	04 Jan 2018	BUY	3.80
26 Feb 2019	BUY	4.60	31 Oct 2017	BUY	3.30
20 Jan 2019	BUY	3.75	01 Aug 2017	BUY	3.10
03 Dec 2018	BUY	3.45	17 Jul 2017	BUY	3.00
09 Oct 2018	BUY	2.75	22 Apr 2017	BUY	2.98*
30 Jul 2018	BUY	2.80	28 Feb 2017	BUY	3.38*
27 Jun 2018	BUY	3.10	14 Dec 2016	BUY	3.48*
05 Jun 2018	BUY	3.50	18 Oct 2016	BUY	3.87*
24 Jan 2018	BUY	4.10			

Source: CLSA; \* Adjusted for corporate action





Sep 16 Jan 17 May 17 Sep 17 Jan 18 May 18 Sep 18 Jan 19 May 19

Date	Rec	Target	Date	Rec	Target
04 Jun 2019	O-PF	25.50	29 Apr 2018	BUY	37.60
29 Apr 2019	O-PF	30.50	19 Mar 2018	BUY	38.40
16 Jan 2019	O-PF	28.10	24 Jan 2018	BUY	39.00
03 Dec 2018	BUY	28.80	27 Oct 2017	BUY	36.30
26 Oct 2018	BUY	30.00	15 May 2017	BUY	32.60
22 Aug 2018	BUY	34.00			
Source: CLSA					

The policy of CLSA and CL Securities Taiwan Co., Ltd. ("CLST") is to only publish research that is impartial, independent, clear, fair, and not misleading. Regulations or market practice of some jurisdictions/markets prescribe certain disclosures to be made for certain actual, potential or perceived conflicts of interests relating to a research report as below. This research disclosure should be read in conjunction with the research disclaimer as set out at www.clsa.com/disclaimer.html and the applicable regulation of the concerned market where the analyst is stationed and hence subject to. Investors are strongly encouraged to review this disclaimer before investing.

Neither analysts nor their household members/associates/may have a financial interest in, or be an officer, director or advisory board member of companies covered by the analyst unless disclosed herein. In circumstances where an analyst has a pre-existing holding in any securities under coverage, those holdings are grandfathered and the analyst is prohibited from trading such securities.

Unless specified otherwise, CLSA/CLST or its respective affiliates, did not receive investment banking/non-investment banking income from, and did not manage/co-manage a public offering for, the listed company during the past 12 months, and it does not expect to receive investment banking compensation from the listed company within the coming three months. Unless mentioned otherwise, CLSA/CLST does not own 1% or more of any class of securities of the subject company, and does not make a market, in the securities. (For full disclosure of interest for all companies mention on this report, please refer to http://www.clsa.com/member/research\_disclosures/ for details.)

The analysts included herein hereby confirm that they have not been placed under any undue influence, intervention or pressure by any person/s in compiling this research report. In addition, the analysts attest that they were not in possession of any material, nonpublic information regarding the subject company at the time of publication of the report. Save from the disclosure below (if any), the analyst(s) is/are not aware of any material conflict of interest.

As analyst(s) of this report, I/we hereby certify that the views expressed in this research report accurately reflect my/our own personal views about the securities and/or the issuers and that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation or views contained in this report or to any investment banking relationship with the subject company covered in this report (for the past one year) or otherwise any other relationship with such company which leads to receipt of fees from the company except in ordinary course of business of the company. The analyst/s also state/s and confirm/s that he/she/they has/have not been placed under any undue influence, intervention or pressure by any person/s in compiling this research report. In addition, the analysts included herein attest that they were not in possession of any material, nonpublic information regarding the subject company at the time of publication of the report. The analysts further confirm that none of the information used in this report was received from CLSA's Corporate Finance department or CLSA's Sales and Trading business. Save from the disclosure below (if any), the analyst(s) is/are not aware of any material conflict of interest.

Key to CLSA/CLST investment rankings: BUY: Total stock return (including dividends) expected to exceed 20%; O-PF: Total expected return below 20% but exceeding market return; U-PF: Total expected return positive but below market return; SELL: Total return expected to be negative. For relative performance, we benchmark the 12month total forecast return (including dividends) for the stock against the 12-month forecast return (including dividends) for the market on which the stock trades.

We define as "Double Baggers" stocks we expect to yield 100% or more (including dividends) within three years at the time the stocks are introduced to our "Double Bagger" list. "High Conviction" Ideas are not necessarily stocks with the most upside/downside, but those where the Research Head/Strategist believes there is the highest likelihood of positive/negative returns. The list for each market is monitored weekly.

Overall rating distribution for CLSA (exclude CLST) only Universe: Overall rating distribution: BUY / Outperform - CLSA: 70.43%, Underperform / SELL - CLSA: 35.30%, Restricted - CLSA: 0.00%; Data as of 31 March 2019. Investment banking clients as a % of rating category: BUY / Outperform - CLSA: 0.32%, Underperform / SELL -CLSA: 0.16%; Restricted - CLSA: 0.00%. Data for 12-month period ending 31 March 2019.

Overall rating distribution for CLST only Universe: Overall rating distribution: BUY / Outperform - CLST: 52.31%, Underperform / SELL - CLST: 47.69%, Restricted - CLST: 0.00%. Data as of 31 March 2019. Investment banking clients as a % of rating category: BUY / Outperform - CLST: 0.00%, Underperform / SELL - CLST: 0.00%, Restricted - CLST: 0.00%. Data for 12-month period ending 31 March 2019. There are no numbers for Hold/Neutral as CLSA/CLST do not have such investment rankings. For a history of the recommendation, price targets and disclosure information for companies mentioned in this report please write to: CLSA Group Compliance, 18/F, One Pacific Place, 88 Queensway, Hong Kong and/or; (c) CLST Compliance (27/F, 95, Section 2 Dun Hua South Road, Taipei 10682, Taiwan, telephone (886) 2 2326 8188). EVA® is a registered trademark of Stern, Stewart & Co. "CL" in charts and tables stands for CLSA estimates, "CT" stands for CLST estimates, "CRR" stands for CRR Research estimates and "CS" for Citic Securities estimates unless otherwise noted in the source.

This publication/communication is subject to and incorporates the terms and conditions of use set out on the www.clsa.com website (https://www.clsa.com/disclaimer.html). Neither the publication/communication nor any portion hereof may be reprinted, sold, resold, copied, reproduced, distributed, redistributed, published, republished, displayed, posted or transmitted in any form or media or by any means without the written consent of CLSA and/or CLST. CLSA CLST has/have and/or produced this publication/communication for private circulation to professional, institutional and/or wholesale clients only, and may not be distributed to retail investors. The information, opinions and estimates herein are not directed at, or intended for distribution to or use by, any person or entity in any jurisdiction where doing so would be contrary to law or regulation or which would subject CLSA, and/or CLST to any additional registration or licensing requirement within such jurisdiction. The information and statistical data herein have been obtained from sources we believe to be reliable. Such information has not been independently verified and we make no representation or warranty as to its accuracy, completeness or correctness. Any opinions or estimates herein reflect the judgment of CLSA and/or CLST at the date of this publication/communication and are subject to change at any time without notice. Where any part of the information, opinions or estimates contained herein reflects the views and opinions of a sales person or a non-analyst, such views and opinions may not correspond to the published view of CLSA and/or CLST. Any price target given in the report may be projected from one or more valuation models and hence any price target may be subject to the inherent risk of the selected model as well as other external risk factors. Where the publication does not contain ratings, the material should not be construed as research but is offered as factual commentary. It is not intended to, nor should it be used to form an investment opinion about the non-rated companies.

This publication/communication is for information purposes only and it does not constitute or contain, and should not be considered as an offer or invitation to sell, or any solicitation or invitation of any offer to subscribe for or purchase any securities in any jurisdiction and recipient of this publication/communication must make its own independent decisions regarding any securities or financial instruments mentioned herein. This is not intended to provide professional, investment or any other type of advice or recommendation and does not take into account the particular investment objectives, financial situation or needs of individual Before acting on any information recipients. in this publication/communication, you should consider whether it is suitable for your particular circumstances and, if appropriate, seek professional advice, including tax advice. Investments involve risks, and investors should exercise prudence and their own judgment in making their investment decisions. The value of any investment or income my go down as well as up, and investors may not get back the full (or any) amount invested. Past performance is not necessarily a guide to future performance. CLSA and/or CLST do/does not accept any responsibility and cannot be held liable for any person's use of or reliance on the information and opinions contained herein. To the extent permitted by applicable securities laws and regulations, CLSA and/or CLST accept(s) no liability whatsoever for any direct or consequential loss arising from the use of this publication/communication or its contents.

To maintain the independence and integrity of our research, our Corporate Finance, Sales Trading, Asset Management and Research business lines are distinct from one another. This means that CLSA's Research department is not part of and does not report to CLSA Corporate Finance department or CLSA's Sales and Trading business. Accordingly, neither the Corporate Finance nor the Sales and Trading department supervises or controls the activities of CLSA's research analysts. CLSA's research analysts report to the management of the Research department, who in turn report to CLSA's senior management. CLSA has put in place a number of internal controls designed to manage conflicts of interest that may arise as a result of CLSA engaging in Corporate Finance, Sales and Trading, Asset Management and Research activities. Some examples of these controls include: the use of information barriers and other controls designed to ensure that confidential information is only shared on a "need to know" basis and in compliance with CLSA's Chinese Wall policies and procedures; measures designed to ensure that interactions that may occur among CLSA's Research personnel, Corporate Finance, Asset Management, and Sales and Trading personnel, CLSA's financial product issuers and CLSA's research analysts do not compromise the integrity and independence of CLSA's research.

Subject to any applicable laws and regulations at any given time, CLSA, CLST, their respective affiliates, officers, directors or employees may have used the information contained herein before publication and may have positions in, or may from time to time purchase or sell or have a material interest in any of the securities mentioned or related securities, or may currently or in future have or have had a business or financial relationship with, or may provide or have provided corporate finance/capital markets and/or other services to, the entities referred to herein, their advisors and/or any other connected parties. As a result, you should be aware that CLSA and/or CLST and/or their respective affiliates, officers, directors or employees may have one or more conflicts of interest. Regulations or market practice of some jurisdictions/markets prescribe certain disclosures to be made for certain actual, potential or perceived conflicts of interests relating to research reports. Details of the disclosable interest can be found in certain reports as required by the relevant rules and regulation and the full details are available at http://www.clsa.com/member/research\_disclosures/. Disclosures therein include the position of CLSA and CLST only. Unless specified otherwise, CLSA did not receive any compensation or other benefits from the subiect company, covered in this publication/communication, or from any third party. If investors have difficulty accessing this website, please contact anv webadmin@clsa.com on +852 2600 8111. If you require disclosure information on previous dates. please contact compliance\_hk@clsa.com.

This publication/communication is distributed for and on behalf of CLSA Limited (for research compiled by non-US and non-Taiwan analyst(s)), and/or CLST (for research compiled by Taiwan analyst(s)) in Australia by CLSA Australia Pty Ltd; in Hong Kong by CLSA Limited; in India by CLSA India Private Limited, (Address: 8/F, Dalamal House, Nariman Point, Mumbai 400021. Tel No: +91-22-66505050. Fax No: +91-22-22840271; CIN: U67120MH1994PLC083118; SEBI Registration No: INZ000001735 as Stock Broker, INM000010619 as Merchant Banker and INH000001113 as Research Analyst,; in Indonesia by PT CLSA Sekuritas Indonesia; in Japan by CLSA Securities Japan Co., Ltd.; in Korea by CLSA Securities Korea Ltd.; in Malaysia by CLSA Securities Malaysia Sdn. Bhd.; in the Philippines by CLSA Philippines Inc (a member of Philippine Stock Exchange and Securities Investors Protection Fund); in Singapore by CLSA Singapore Pte Ltd and solely to persons who qualify as an "Institutional Investor", "Accredited Investor" or "Expert Investor"; in Thailand by CLSA Securities (Thailand) Limited; in Taiwan by CLST and in United Kingdom by CLSA (UK).

United States of America: Where any section is compiled by non-US analyst(s), it is distributed into the United States by CLSA solely to persons who qualify as "Major US Institutional Investors" as defined in Rule 15a-6 under the Securities and Exchange Act of 1934 and who deal with CLSA Americas. However, the delivery of this research report to any person in the United States shall not be deemed a recommendation to effect any transactions in the securities discussed herein or an endorsement of any opinion expressed herein. Any recipient of this research in the United States wishing to effect a transaction in any security mentioned herein should do so by contacting CLSA Americas.

United Kingdom: In the United Kingdom, this research is a marketing communication. It has not been prepared in accordance with the legal requirements designed to promote the independence of investment research, and is not subject to any prohibition on dealing ahead of the dissemination of investment research. The research is disseminated in the EU by CLSA (UK), which is authorised and regulated by the Financial Conduct Authority. This document is directed at persons having professional experience in matters relating to investments as defined in Article 19 of the FSMA 2000 (Financial Promotion) Order 2005. Any investment activity to which it relates is only available to such persons. If you do not have professional experience in matters relating to investments you should not rely on this document. Where the research material is compiled by the UK analyst(s), it is produced and disseminated by CLSA (UK). For the purposes of the Financial Conduct Rules this research is prepared and intended as substantive research material.

For all other jurisdiction-specific disclaimers please refer to https://www.clsa.com/disclaimer.html. The analysts/contributors to this publication/communication may be employed by any relevant CLSA entity or CLST, which is different from the entity that distributes the publication/communication in the respective jurisdictions.© 2019 CLSA Limited and/or CL Securities Taiwan Co., Ltd. ("CLST").